

J I A C D

The Journal of Implant & Advanced Clinical Dentistry


Choukroun's Platelet Rich Fibrin (PRF)



**Immediate Loading
with Zirconia Abutments**

2 Hours of CE Credit

esthetics enhanced by technology



Laser-Lok® dental implant at 8 years post-restoration showing superior crestal bone & tissue maintenance.

Case courtesy of Cary A. Shapoff, DDS (Surgical); Jeffrey A. Babushkin, DDS (Restorative)

Laser-Lok® microchannels

BioHorizons is known for using science and innovation to create unique implants with proven surgical and esthetic results. Laser-Lok microchannels exemplify our dedication to evidence-based research and development.

The effectiveness of Laser-Lok has been proven with over 15 years of *in vitro*, animal, and human studies at leading universities.[†] This patented precision laser surface treatment is unique within the industry as the only surface treatment shown to inhibit epithelial downgrowth, attract a true, physical connective tissue attachment to a predetermined zone on the implant and preserve the coronal level of bone; long term.[‡]

Laser-Lok is available on Tapered Internal, Single-stage, and Internal Implants.



For more information, contact BioHorizons
Customer Care: 1.888.246.8338 or
shop online at www.biohorizons.com

[†]Clinical References available. [‡]Human Histologic Evidence of a Connective Tissue Attachment to a Dental Implant. M Nevins, ML Nevins, M Camelo, JL Boyesen, DM Kim. The International Journal of Periodontics & Restorative Dentistry. Vol. 28, No. 2, 2008.

OSTEOGENICS' 2010 GLOBAL BONE GRAFTING SYMPOSIUM

FOCUS: TREATMENT PLANNING ROUTINE AND COMPLEX BONE GRAFTING CASES
WESTIN KIERLAND RESORT & SPA :: SCOTTSDALE, ARIZONA :: MAR 26-27, 2010



H. DEXTER
BARBER, DDS



SUZANNE
CAUDRY, PHD,
DDS, MSC



DANIEL
CULLUM, DDS



ANDREAS
SIEBOLD,
BCHD, MCHD,
DR.MED.DENT



HOM-LAY
WANG, DDS,
MSD, PHD



THOMAS
WILSON, JR.,
DDS

KEYNOTE SPEAKER:
MICHAEL PIKOS, DDS



LEARN MORE



SYMPOSIUM REGISTRATION

\$695 :: REGISTER BY FEB 26TH, 2010 (NONREFUNDABLE AFTER FEB 26TH, 2010)

ASSISTANTS AND OFFICE PERSONNEL ARE WELCOME AT \$250/PERSON

CALL LAURA WOOD AT 1.888.796.1923 OR VISIT WWW.OSTEOGENICS.COM/COURSES TO REGISTER.





Say Goodbye To Impression Copings

Introducing The Encode® Impression System

***Ask Your Surgeon To Place Encode Healing Abutments
Available Exclusively Through BIOMET 3i***

Call Your BIOMET 3i Representative Today. In The USA: 1-800-342-5454
Outside The USA: +1-561-776-6700 Or Visit Us Online At www.biomet3i.com


Encode is a registered trademark of BIOMET 3i LLC. BIOMET is a registered trademark and BIOMET 3i and design are trademarks of BIOMET, Inc. ©2009 BIOMET 3i LLC. All rights reserved.

Optimal Site Preservation



Bio-Oss® produced more favorable results than allogenic materials for the preservation of extraction sockets prior to dental implantation¹

- The long-term osteoconductive scaffold, Bio-Oss® induced more new bone deposition than allografts and exhibited increased osteoblastic activity.
- Rapid resorption of the allografts resulted in more fibrous connective tissue and less new bone than Bio-Oss®.



Histograms showing the percentages of (left) new bone, (middle), residual graft particles, and (right) fibrous connective tissue in the biopsy specimens. *Significant difference ($P < .05$) T = 4.5 months; n = 20



To learn more, please visit us online at www.ostehealth.com or call 1-800-874-2334


References: ¹Lee DW, Pi SH, Lee SK, Kim EC. Comparative Histomorphometric Analysis of Extraction Sockets Healing Implanted with Bovine Xenografts, Irradiated Cancellous Allografts, and Solvent-Dehydrated Allografts in Humans. Int J Oral Maxillofac Implants 2009; 24: 609-615. Bio-Oss® is a registered trademarks of Ed. Geistlich Söhne Ag Fur Chemische Industrie and is marketed under license by Osteohealth, a Division of Luitpold Pharmaceuticals, Inc. Puros® is a registered trademark of Zimmer, Inc. ©2009 Luitpold Pharmaceuticals, Inc. OHD239 Iss. 9/2009

The Only **Dual Stabilization®
Dental Implant System**
Designed and Manufactured in the USA. 

Single stage, flapless surgery or conventional surgical placement
Self-tapping implant, designed for delayed or immediate loading
Multiple Complete direct and indirect restorative systems available

1mm Titanium Nitride esthetic collar
Proven mountless internal interface
New Scalloped Abutment available

[Introducing]
THE NEW **ERI**
With Dual Stabilization®



- A** Bull-nose/Auger tip condenses bone and creates a biomechanical lock. This stabilizes the apex of the implant by creating tension and pulling bone around the tip.
- B** Mini Cortic-O Thread™ locks into cortical bone and stabilizes the top of the implant.
- C** Natural Profile Abutment for soft tissue contouring & emergence profile

The Next Generation of Esthetic Implants for \$179

Offer your patients a high quality/low cost dental implant that places a temporary tooth in the esthetic zone in less than an hour. The ERI's self tapping implant body is the same as the proven ISI Complete® One-Piece and TSI Two-Piece (with over 7 years of refinement and an unchallenged reported success rate). The new ERI implant also has a 1mm titanium nitride perioclock collar to camouflage itself under the gingiva, thus eliminating any grey titanium bleed-through. The ERI Dual Stabilization® implant body maximizes thread to bone fixation and is designed to stabilize the tip and collar to allow for immediate loading.

To learn more about the Dual Stabilization® Dental Implant System or how our one-day training program can improve your profitability, Call 800.228.0477

Upcoming Training Dates:

February 20th - Dallas, TX
March 20th - Chicago, IL
April 3rd - Sacramento, CA
May 21st - Albuquerque, NM
June 5th - Las Vegas, NV



OCO BIOMEDICAL


800.228.0477 | ocobiomedical.com

Table of Contents

20 Case of the Month


Implant Replacement with Minimally Invasive Surgery and Immediate Loading in the Esthetic Zone Utilizing a Zirconia Abutment and Ceramic Restoration

Jaeseok Kim




27 Use of an Autologous Leukocyte and Platelet-Rich Fibrin (L-PRF) Membrane in Post-Avulsion Sites: An Overview of Choukroun's PRF

Marco Del Corso, Michael Toffler,
David M. Dohan Ehrenfest



39 Ridge Split Technique Using Ultrasonic Surgical System: A Case Report

Kurt G. Hummeldorf, Brian B. Chang,
Philip Vance



Free CPS kit with every implant!



The Complete Prosthetic Set has been designed to enable an easy impression and transfer technique. It combines solutions for both bridges and single crowns and enables a simple restorative process without necessary adjustments, nor additional elements. The Complete Prosthetic Set ensures an accurate fit for the final restoration.

MIS
Make it Simple

MIS offers a wide range of innovative kits and accessories that provide creative and simple solutions for the varied challenges encountered in implant dentistry.

To learn more about MIS visit our website at:

misimplants.com

or call us: **866-797-1333** (toll free)




Order 10 implants of your choice and get a Free CPS Kit with each implant.

* Abutment (A), Abutment Analog (B), Impression Transfer (C).

Table of Contents


47 Evaluation of Maxillary Osseous Lesion using CBCT in a Patient with Multiple Myeloma

Werner Harumiti Shintaku, Marcel Noujeim, Vidya Sankar




55 Successful Treatment Using Dental Implants in Patients with Systemic Sclerosis: A Report on Two Cases

Mami Nakadai, Hiroyasu Endo, Terry D. Rees, Hiroyuki Tamaki, Hiroyuki Okada, Takao Kato, Hirotosugu Yamamoto



65 JIACD Continuing Education Factors Driving Peri-implant Crestal Bone Loss - Literature Review and Discussion: Part 3

Mohammad Ketabi, Robert Pilliar, Douglas Deporter





SURGICAL SUPPLY CO., INC.

800.441.3100

Osteocel®

The Future Is Now.

A Bone Matrix Product Containing Stem Cells.

The Properties of Autograft without Associated Risks

The proprietary processing technology that produces Osteocel® results in a viable bone matrix product that preserves the native stem cells found in marrow rich bone. It is the only product available today that has the desired beneficial properties of autograft - osteoconduction, osteoinduction and osteogenesis — and that allows surgeons to provide their patients with optimal bone growth conditions without the added risk and cost of a secondary procedure.

Low Immunogenicity

Mesenchymal stem cells are IMMUNE-PRIVILEGED cells that do not stimulate a cellular immune response. Osteocel does not activate T cell proliferation, as shown *in vitro* from Mixed Lymphocyte Reaction (MLR) testing.

Histologic Evidence

Positive clinical use of Osteocel since 2005 demonstrates bone-forming ability. Histology from a human sinus augmentation study using Osteocel shows substantial vital bone content at 16 weeks, with very low residual graft material.¹

Bone Formation

Stem cells contained in Osteocel are capable of differentiating into bone cells. Every lot of Osteocel is tested for bone forming potential.


Viable Cell Content

The osteogenic potential arises from the stem cells in Osteocel. Following processing of marrow-rich bone, release testing demonstrates osteogenic potential according to the following criteria:

- Rich supply of stem cells: Greater than 50,000 cells/cc
- Viability: Greater than 70% cell viability
- Positive osteogenesis: In vitro cell culture assay

For more information or to place an order call 800.441.3100

¹ Histologic Evaluation of a Stem Cell Based Sinus Augmentation Procedure: A Case Series. — McAllister, Haghighat, Gonshor. — Journal of Perio., April 2009



Ridge Augmentation clinical case.


www.acesurgical.com

ACE Surgical Supply Company, Inc. • 1034 Pearl Street, Brockton, MA 02301

An Evening Lecture Series

- January 14th • NYC / Long Island
- January 27th • Palo Alto, CA
- February 4th • New Jersey
- February 11th • Cleveland, OH
- March 1st • Fort Lauderdale, FL

- March 3rd • Tampa, FL
- March 4th • Orlando, FL
- March 11th • Atlanta, GA
- March 23rd • Chicago, IL
- April 1st • Boston, MA



To Register, please call **800.441.3100**

J I A C D

The Journal of Implant & Advanced Clinical Dentistry

VOLUME 1, No. 9 • DECEMBER/JANUARY 2010

Publisher

SpecOps Media, LLC

Design

Jimmydog Design Group

www.jimmydog.com

Production Manager

Stephanie Belcher

336-201-7475

Copy Editor

JACD staff

Digital Conversion

NxtBook Media

Internet Management

InfoSwell Media

Subscription Information: Annual rates as follows:
Non-qualified individual: \$99(USD) Institutional: \$99(USD).
For more information regarding subscriptions,
contact info@jiacd.com or 1-888-923-0002.

Advertising Policy: All advertisements appearing in the Journal of Implant and Advanced Clinical Dentistry (JIACD) must be approved by the editorial staff which has the right to reject or request changes to submitted advertisements. The publication of an advertisement in JIACD does not constitute an endorsement by the publisher. Additionally, the publisher does not guarantee or warrant any claims made by JIACD advertisers.

For advertising information, please contact:

info@JIACD.com or 1-888-923-0002

Manuscript Submission: JIACD publishing guidelines can be found at <http://www.jiacd.com/author-guidelines> or by calling 1-888-923-0002.

Copyright © 2009 by SpecOps Media, LLC. All rights reserved under United States and International Copyright Conventions. No part of this journal may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying or any other information retrieval system, without prior written permission from the publisher.

Disclaimer: Reading an article in JIACD does not qualify the reader to incorporate new techniques or procedures discussed in JIACD into their scope of practice. JIACD readers should exercise judgment according to their educational training, clinical experience, and professional expertise when attempting new procedures. JIACD, its staff, and parent company SpecOps Media, LLC (hereinafter referred to as JIACD-SOM) assume no responsibility or liability for the actions of its readers.

Opinions expressed in JIACD articles and communications are those of the authors and not necessarily those of JIACD-SOM. JIACD-SOM disclaims any responsibility or liability for such material and does not guarantee, warrant, nor endorse any product, procedure, or technique discussed in JIACD, its affiliated websites, or affiliated communications. Additionally, JIACD-SOM does not guarantee any claims made by manufacturers of products advertised in JIACD, its affiliated websites, or affiliated communications.

Conflicts of Interest: Authors submitting articles to JIACD must declare, in writing, any potential conflicts of interest, monetary or otherwise, that may exist with the article. Failure to submit a conflict of interest declaration will result in suspension of manuscript peer review.

Erratum: Please notify JIACD of article discrepancies or errors by contacting editors@JIACD.com

JIACD (ISSN 1947-5284) is published on a monthly basis by SpecOps Media, LLC, Saint James, New York, USA.



simply smarter.

27030 Malibu Hills Road,
Calabasas Hills, CA 91301
Phone: 1-818-444-3333
www.implantdirect.com

****SwissPlant's All-in-One packaging includes: Cover Screw, Healing Collar, Transfer and Straight Abutment with Snap-on Comfort Cap**

SwissPlant USA price = \$200

Straumann USA price = \$632



Straumann Customers

Why choose between a Tissue-Level or Bone-Level Implant when you can use SwissPlant, with *surgical and prosthetic compatibility, for both applications and save over \$400** per tooth replacement?

FEATURES AND BENEFITS

1. Body Design: Tapered with double-lead buttress threads
2. Surface/Body: SBM Medium Texture with 17 year history
3. Surface/Neck: SBM Light Texture for soft or hard tissue
4. Diameters: Standard 4.1mm and 4.8mm plus 3.3mm & 5.7mm
5. Platforms: Standard 4.8mm and 6.5mm internal octagon plus 3.7mm hex with Platform Switch
6. Fixture-mount/Transfer/Abutment: Engages square within octagon



* The 4.1mm and 4.8mm SwissPlant implants can be inserted into soft bone using Straumann's drills. An additional drill is required for dense bone or countersinking for bone-level placement. Implant Direct's ratchet, insertion tool and 1.25mmD hex tool are also required.

Recommended Introductory offer for ITI Straumann® users
3 Free SwissPlant Implants with Internal connection, External Bevel, plus "Solid" Engaging Abutments and Transfers

US List Price for 3 Implants, Abutments and Prosthetic Components:

SwissPlant = \$690

ITI Straumann = \$2032



Compare US List Price	Ball Attachment	Screw Receiving	Straight Snap-On	Straight Solid Abutment	Preparable Covers Bevel	Preparable Platform Switch	15° Angled	Gold/Plastic	Temporary Abutment	Locator Abutment
Implant Direct	\$107	\$85	\$85	\$85	\$85	\$85	\$85	\$100	\$35	\$138
ITI Straumann	\$162	\$182	\$185	\$185	\$182	\$182	\$203	\$211	\$61	\$138
Cost Savings	44%	53%	54%	54%	59%	59%	58%	53%	43%	0%

FREE Introductory Offers at
www.implantdirect.com

List prices as of 3/15/09

Founder, Co-Editor in Chief

Dan Holtzclaw, DDS, MS

Founder, Co-Editor in Chief

Nicholas Toscano, DDS, MS

Editorial Advisory Board

Tara Aghaloo, DDS, MD
Faizan Alawi, DDS
Michael Apa, DDS
Alan M. Atlas, DMD
Charles Babbush, DMD, MS
Thomas Balshi, DDS
Barry Bartee, DDS, MD
Lorin Berland, DDS
Peter Bertrand, DDS
Michael Block, DMD
Chris Bonacci, DDS, MD
Hugo Bonilla, DDS, MS
Gary F. Bouloux, MD, DDS
Ronald Brown, DDS, MS
Bobby Butler, DDS
Donald Callan, DDS
Nicholas Caplanis, DMD, MS
Daniele Cardaropoli, DDS
Giuseppe Cardaropoli DDS, PhD
John Cavallaro, DDS
Stepehn Chu, DMD, MSD
David Clark, DDS
Charles Cobb, DDS, PhD
Spyridon Condos, DDS
Sally Cram, DDS
Tomell DeBose, DDS
Massimo Del Fabbro, PhD
Douglas Deporter, DDS, PhD
Alex Ehrlich, DDS, MS
Nicolas Elian, DDS
Paul Fugazzotto, DDS
Scott Ganz, DMD
Arun K. Garg, DMD
David Guichet, DDS
Kenneth Hamlett, DDS
Istvan Hargitai, DDS, MS
Michael Herndon, DDS
Robert Horowitz, DDS
Michael Huber, DDS

Richard Hughes, DDS
Debby Hwang, DMD
Mian Iqbal, DMD, MS
Tassos Irinakis, DDS, MSc
James Jacobs, DMD
Ziad N. Jalbout, DDS
John Johnson, DDS, MS
Sascha Jovanovic, DDS, MS
John Kois, DMD, MSD
Jack T Krauser, DMD
Gregori Kurtzman, DDS
Burton Langer, DMD
Aldo Leopardi, DDS, MS
Edward Lowe, DMD
Shannon Mackey
Miles Madison, DDS
Carlo Maiorana, MD, DDS
Jay Malmquist, DMD
Louis Mandel, DDS
Michael Martin, DDS, PhD
Ziv Mazor, DMD
Dale Miles, DDS, MS
Robert Miller, DDS
John Minichetti, DMD
Uwe Mohr, MDT
Jaimee Morgan, DDS
Dwight Moss, DMD, MS
Peter K. Moy, DMD
Mel Mupparapu, DMD
Ross Nash, DDS
Gregory Naylor, DDS
Marcel Noujeim, DDS, MS
Sammy Noubissi, DDS, MS
Arthur Novaes, DDS, MS
Andrew M. Orchin, DDS
Charles Orth, DDS
Jacinthe Paquette, DDS
Adriano Piattelli, MD, DDS
Stan Presley, DDS

George Priest, DMD
Giulio Rasperini, DDS
Michele Ravenel, DMD, MS
Terry Rees, DDS
Laurence Rifkin, DDS
Georgios E. Romanos, DDS, PhD
Paul Rosen, DMD, MS
Joel Rosenlicht, DMD
Larry Rosenthal, DDS
Steven Roser, DMD, MD
Salvatore Ruggiero, DMD, MD
Anthony Sclar, DMD
Frank Setzer, DDS
Maurizio Silvestri, DDS, MD
Dennis Smiler, DDS, MScD
Dong-Seok Sohn, DDS, PhD
Muna Soltan, DDS
Michael Sonick, DMD
Ahmad Soolari, DMD
Christian Stappert, DDS, PhD
Neil L. Starr, DDS
Eric Stoopler, DMD
Scott Synnott, DMD
Haim Tal, DMD, PhD
Gregory Tarantola, DDS
Dennis Tarnow, DDS
Geza Terezhalmay, DDS, MA
Tiziano Testori, MD, DDS
Michael Tischler, DDS
Michael Toffler, DDS
Tolga Tozum, DDS, PhD
Leonardo Trombelli, DDS, PhD
Ilser Turkyilmaz, DDS, PhD
Dean Vafiadis, DDS
Hom-Lay Wang, DDS, PhD
Benjamin O. Watkins, III, DDS
Alan Winter, DDS
Glenn Wolfinger, DDS
Richard K. Yoon, DDS

**Sybron
Implant Solutions**
SYBRON DENTAL SPECIALTIES

UNCOMPROMISED QUALITY. EXTRAORDINARY VALUE.

Straumann® compatible Internal Octagon Morse Taper prosthetic connection.

Precision engineered and built on a proven platform, the SybronPRO™ TL implant incorporates additional features such as self-tapping threads and a mount-free delivery system.

Why pay more?

Purchase 20 implants
Receive Free
Surgical Kit

Purchase 50 implants
Receive Free
Surgical Kit
2 Implants
50 Healing Abutments

Purchase 100 implants
Receive Free
2 Surgical Kits
10 Implants
100 Healing Abutments

SPECIAL
\$149 USD/implant*
(List Price \$345 USD/implant)

Contact us today to experience the extraordinary!
1-800-718-5157 • www.sybronimplants.com

*Limited Time Offer, Restrictions May Apply.

Celebrating over 100 years of dental excellence

Kerr

Orascopic

SybronEndo

Ormco

Attachments
International

KERR
TotalCare

GENDEX

AV
16

Peterson's
Cure

Sybron
Implant Solutions

DEXIS

Imaging
Sciences
International

Seita

Year One

As we draw closer to the end of the year 2009, JIACD has many reasons to give thanks. First and foremost, Nick and I would like to thank YOU for reading JIACD. Without you, there would be no need for JIACD. We do our best to turn out a product that meets the wants and desires of real life clinicians. Judging the response that we have received from our readers so far, we think that we are meeting this goal.

Did you know that since JIACD was launched in March of 2009, we have had an astounding *2.8 million* page views of the journal? Did you know that JIACD is read in 104 countries? Every month, when we review the journal's readership statistics, Nick and I are quite amazed to see that JIACD is read in nearly every country on the planet. That is really quite amazing, especially when you consider that JIACD has been in existence for less than one year.

Our explosive growth is attributed to many factors. Obviously, the internet is key reason why JIACD has been able to grow so quickly and attain a worldwide reach. With the internet, anyone with a computer has free and instant access to JIACD. This leads us to reason number two for our explosive growth: FREE and INSTANT. When you want to know something, you want the information NOW and you want it for free. JIACD gives this to you. All issues of JIACD are always available on our website www.JIACD.com 24 hours per day, 7 days per week, 365 days per year. If you want to read a JIACD article to enhance your knowledge of dentistry, you simply visit the JIACD website and get what you need. There is no ordering anything, there is no paying for anything, and there is no waiting for a copy of the article to arrive by ancient land based mail. When you want it, you get it and you get it now!

In addition to reasons one and two, we also like to think that JIACD has attracted many readers based on the quality of its content. JIACD has published many high quality articles from some of the most respected names in dentistry. We

have been the first to publish many cutting edge procedures and show cases that highlight the future of implant and advanced clinical dentistry.

We are very proud of the fact that JIACD has gained a reputation as one of the most user friendly journals for article publication. For example, many authors to whom English is a second language have an extremely difficult time getting their articles published in English based journals. While the underlying content of these authors' articles are very good, communication barriers often lead to the rejection of their publication. In many cases, JIACD has assisted such authors with retooling their article for publication in an English based journal. With other journals, this task is left to the author alone and this is the reason why many of these great articles never make it to publication. JIACD does not believe in this model of placing all burdens on the author. If there is good information to be passed along to our colleagues in implant and advanced clinical dentistry, JIACD pledges to always assist the author in making this knowledge available to all. Just ask anyone who has published with JIACD about their experience. Undoubtedly, the responses will be positive and that makes us extremely proud. If you have not published with JIACD, we strongly encourage you to do so. Everyone has something to contribute.

With the second decade of the new millennium approaching, JIACD anticipates many more great things to come. We have a number of new interactive features planned for the journal which will ultimately benefit all in clinical practice. We thank you for your support and look forward to providing you with many more issues that will benefit you and your patients. ●




Dan Holtzclaw, DDS, MS
Founder, Co-Editor-In-Chief



Nick Toscano, DDS, MS
Founder, Co-Editor-In-Chief

RIEMSER: Expanding our leadership in bone regeneration



RIEMSER has brought you Cerasorb[®], EpiGuide[®] and the new Bacterin allograft line – all unique, top-quality, high-value bone regeneration products – to meet your needs.

Coming soon: another high-quality addition to further enhance your practice.

To learn more, call our offices or visit us at all major meetings.

RIEMSER



888-237-2767

www.RIEMSERdental.com

Cerasorb[®]

EpiGuide[®]

Bacterin

A Windy Day

At the most recent Academy of Periodontology meeting in Boston, I was fortunate enough to discover five new miracle implants, three life changing bone graft materials and two heaven sent soft tissue allografts.

Everywhere I turned I was offered a chance to use the newest, best, cheapest and easiest implant or grafting material. However, as I stopped and spoke with each representative, the miraculous became mundane.

I asked questions which should be basic inquiries from anybody considering utilization of implants or grafting materials in patients' mouths. In considering an implant, I asked the following:

- What is the implant surface, and how is it prepared?
- What type of histologic data is available documenting the implant's success?
- What independent clinical data has been published, or accepted for publication?
- What are the prosthetic protocols for the implant?
- How do the soft tissues react around the implant following abutment connection and implant restoration?
- What data is available demonstrating the stability of implants restored by these protocols?
- Why should I consider utilization of this implant instead of the implant systems I am currently employing?

Consideration of a grafting material

necessitated obtaining the answers to the following questions:

- Where is the material from?
- How is the material procured, processed and sterilized?
- Does the graft material have any proven osteoinductive capabilities?
- What is the fate of the graft material after implantation?
- What histologic data is available to assess the efficacy and fate of the graft?
- Why should I use this graft material instead of the material I am currently employing?

In short, as Don Corleone said to Salazzo: "What did I do to deserve such generosity?"

Unfortunately, the vast majority of these discussions ended in vague, unsatisfactory responses. Occasionally, statements were actually made which proved misleading at best, and untrue at worst, when further explored.

We are all fortunate enough to practice in a time when proven, predictable implants and regenerative materials abound. While clinicians may have disagreements over which implant system or grafting material to utilize, these disagreements should be grounded in published data and demonstrated success, rather than ad campaigns, pricing or friendships. While practitioners may opt to utilize different implants or graft materials which have demonstrated published proven success, such choices are understandable and wholly acceptable.

It is unacceptable to place implants or graft materials in our patients' mouths because we

J I A C D

The Journal of Implant & Advanced Clinical Dentistry

**ATTENTION
PROSPECTIVE
AUTHORS
JIACD wants
to publish
your article!**

**For complete details
regarding publication in
JIACD, please refer
to our author guidelines at
the following link:**

**[http://www.jiacd.com/
authorinfo/
author-guidelines.pdf](http://www.jiacd.com/authorinfo/author-guidelines.pdf)**

or email us at:

editors@jicad.com

have been swayed by advertiser claims, or are able to obtain these materials at a lesser price than proven alternatives.

It is also important to assess “proof” when it is presented to us. Company sponsored and directed studies, or papers published by “clinical consultants” who are paid significant fees, are of little value. Podium presentations about specific products which are underwritten through honoraria paid directly to the speakers by companies must bear the taint of potential bias. The most appropriate means by which to determine which implant systems and graft materials to utilize is through a combination of critical examination of unbiased literature and discussions with respected colleagues whom you trust to truthfully relate their clinical experiences.

Our patients come to us in trust and ask us to help them. We must be worthy of this trust, as well as being true to ourselves.

To quote the great philosopher Confucius: “There are things you do, and things you do not do.”

These choices define us as clinicians, and ultimately as people. ●



**Paul Fugazzotto, DDS
Private practice limited to
Periodontics and Dental Implants,
Milton, Massachusetts, USA**

SIMPACT

RESILIENCE.

RELATIONSHIPS.

RESULTS.

Your patients turn to you for procedures they can rely on. Now you can turn to us. At Simpect, we are committed to providing innovative products that are designed to offer nothing less than superior results.

Our commitment is based on four cornerstones:

- *Contemporary dental design*
- *Excellent clinical results*
- *Ease of use*
- *Unmatched client support*

In addition to building quality products we're also focused on building quality relationships. We work closely with dental professionals in the design and development of user-friendly systems with you in mind, no matter your area of specialty.

Call us or visit us on the web. Our expert team will be available for advice and direction every step of the way. You'll discover just how dedicated we are to treating your patients' assurance and comfort as seriously as you do.



Patent-Pending
Dental Implant



Successful Bone Regeneration— Strategy Not Chance

Our *in vivo* testing and carrier technology are two strategic moves for improving patient outcomes. Offering only an optimum DBM concentration that is demonstrated by histology* to meet our high osteoinductive standards after sterilization places us in the leading position. Having a human clinical study that proves bone growth...**checkmate!**

Regenaform[®]
MOLDABLE ALLOGRAFT PASTE



© 2009 Exactech, Inc.

Visit us at:

- AAOMS Dental Implant Conference—Dec. 3-6, Chicago, IL, Booth #718

*Each lot of product is tested using the athymic nude rat assay to verify osteoinductive potential.
Regenaform[®] is processed by RTI Biologics, Inc. and distributed by Exactech, Inc.

Exactech[®]
DENTAL BIOLOGICS

www.exac.com/strategy

Change is inevitable. Growth is our choice.

Our family of bone grafting products continues to expand, offering a wide range of effective and cost-conscious options for guided bone regeneration. Oralife™ allografts offer high-quality grafting alternatives for routine grafting procedures. Our precision-machined cortical allograft bone pin is easy-to-prepare, easy-to-use and comes pre-formed to exact specifications the surgeon can rely on time after time. Exactech dental biologics products—**growing to meet your needs.**

Oralife™
Allografts

BonePin
Cortical Allograft



© 2009 Exactech, Inc.

Visit us at:

- AAOMS Dental Implant Conference—Dec. 3-6, Chicago, IL, Booth #718

Oralife allografts are processed by LifeLink Tissue Bank and distributed by Exactech, Inc.
Cortical allograft bone pins are processed by RTI Biologics and distributed by Exactech, Inc.

Exactech®
DENTAL BIOLOGICS

www.exac.com/growth

Case of the Month

Implant Replacement with Minimally Invasive Surgery and Immediate Loading in the Esthetic Zone Utilizing a Zirconia Abutment and Ceramic Restoration

Jaeseok Kim, DMD, MSD, PhD¹ • Chang-Hoon Kim, DDS, MS¹

Abstract

Background: This case report documents minimally invasive implant surgery with immediate loading and prosthodontic treatment utilizing all-ceramic abutment/restorations. Replacement of teeth in the anterior region is always challenging to the clinician. From the patient's perspective, the esthetic quality of restoration is always of the utmost interest. Our aim was to provide immediate and esthetic restoration to the patient.

Methods: The patient was a non-smoking 45 year old female with an unremarkable medical history. Her chief complaint was mobility of the bridge in the maxillary anterior region. After removing the 3-unit bridge, intraoral, extraoral, radiographic, and dental computerized tomography examinations were carried out. The treatment plan included extracting tooth #10 and restoring with implant-supported restorations on #9 and #10. After extraction of #10 and making site preparation using tissue punch on the #9 area, (2) 3.75 x 11.5mm implants (Biomet-3i™, Osseotite®, Palm Beach, CA) were placed. The horizontal gap


between the implant and socket wall was filled with Oragraft® freeze dried bone allograft (LifeNet Health™, Virginia Beach, VA). Initially, the patient wore a provisional removable partial denture. After a one week healing period, a provisional restoration was delivered. Gingival sculpting was performed by using the provisional restoration. After 12 weeks, final impressions were obtained by the restorative dentist. Zirconia abutments using CAD/CAM (Procera System® Nobel Biocare AB, Göteborg, Sweden) and all-ceramic restorations (LAVA, 3M ESPE, St. Paul, MN) were fabricated and delivered to the patient.


Results: The patient was satisfied, regarding the comfort of the operation and the esthetic quality of the definitive restoration.

Conclusions: This case report shows that immediate implant placement and immediate loading using zirconia abutments and restorations offers the clinician and patient simplicity and a high level of esthetics

KEY WORDS: Dental implants, immediate placement, immediate loading, ceramic abutment, ceramic restoration, zirconia

1. Luden Dental Clinic, Seoul, Korea





**Correspondence:**

Jaeseok Kim, DMD, MSD, PhD

Luden Dental Clinic

Eulgiro 2ga, 195-8, Youngsaengilho BLD

Jung-gu, Seoul, Korea

Phone: +82 2 757 2879 • Fax: +82 2 757 7676

<http://www.luden.co.kr>

**WORKING WITH NATURE
TO GIVE YOU THE BEST POSSIBLE
CORTICAL AND CANCELLOUS BONE**

**THE BONE RESTORATION TEAM
IS YOUR FOUNDATION FOR SUCCESS**



- OsteoDemin™ Demineralized Bone Matrix
- NonDemin™ Mineralized Cortical Bone Matrix
- CancellOss™ Mineralized Cancellous Bone Matrix
- CurOss® Mineralized Large Particle Cortical Bone

**BIOPLATE®
BONE AUGMENTATION PLATE AND SCREW SYSTEM**



Implant site devoid of buccal ridge. Debride and decorticate within defect area.

Titanium cage with OsteoGen® and OsteoDemin™

5 months post-op with screws removed and mesh reflected. Ridge improved by 11mm high and 6mm wide.

**OsteoGen®
Synthetic Bioactive
Resorbable Graft**



Pre-filled Syringes

NEW

**PhysioLock®
3D Immediate Implant Stabilization Thread**



- PhysioLock™ 3D Immediate Stabilization Thread (IST)* provides predominant implant Load Bearing Areas for success and increases Total Surface Areas for immediate bone-to-implant interface for the same osteotomy compared to conventional implants
- Lock-In™ anti-rotation thread design uses the viscoelastic properties of bone with 3D osteotomes congruent to implant IST profile
- MicroGroove™ abutment provides immediate abutment-to-bone implant interface
- New high performance thermoplastic cassette is color-coded for fool-proof user friendly surgical sequencing for each implant design



FTI
2010

Future Trends in Implantology
International Dental Conference
November 11-13, 2010,
Florence, Italy

www.ftidental.com

**Abstract Submission
is Now Available**

**Save the
Date
11-13 Nov.
2010**

Preliminary List of Invited Speakers

- | | |
|-----------------------------|-----------------------------------|
| Dr Eduardo Anitua, Spain | Dr Ziv Mazor, Israel |
| Dr R. Cancedda, Italy | Dr Eitan Mijiritsky, Israel |
| Dr Joseph Choukroun, France | Dr Robert Miller, USA |
| Dr Paulo Coelho, USA | Dr Stefano Pagnutti, Italy |
| Dr Danilo Di Stefano, Italy | Dr G. Papaccio, Italy |
| Dr Matteo Danza, Italy | Dr Gabriele Edoardo Pecora, Italy |
| Dr Marco Degidi, Italy | Prof Adriano Piatelli, Italy |
| Dr Stefano Fanali, Italy | Dr Roberto Pistilli, Italy |
| Dr Pietro Felice, Italy | Dr Lorenzo Ravera, Italy |
| Dr Massimo Frosecchi, Italy | Dr U. Ripamonti, South Africa |
| Dr Scott Ganz, USA | Dr Paul Rosen, USA |
| Dr Dan Holtzclaw, USA | Dr Philippe Russe, France |
| Dr Robert Horowitz, USA | Dr Gilberto Sammartino, Italy |
| Dr Michelle Jacotti, Italy | Dr Marius Steigmann, Germany |
| Dr Adi Lorean, Israel | Dr Tiziano Testori, Italy |
| Dr Jack Krauser, USA | Dr Nicholas Toscano, USA |
| Dr Carlo Mangano, Italy | |



Secretariat
Paragon Conventions
18 Avenue Louis-Casai, 1209 Geneva, Switzerland
Tel: +41-(0)-22-5330-948, Fax: +41-(0)-22-5802-953
Email: fti@ftidental.com


January 29th
Grand Hyatt Hotel
New York, New York

January 30th
Intra-Lock CE Center
Boca Raton, Florida

9am-6pm, Didactic morning session &
Hands-on afternoon workshop
8 CE ADA C. E. R. P. credit units

2010 Choukroun lecture series

Platelet-Rich Fibrin



Exclusively Sponsored by



www.intra-lock.com

Limited Attendance. Make your reservations today.


For full details visit us on the web or call Intra-Lock Customer Service: **1 877-330-0338**.



Use of an Autologous Leukocyte and Platelet-Rich Fibrin (L-PRF) Membrane in Post-Avulsion Sites: An Overview of Choukroun's PRF

Marco Del Corso, DDS, DIU¹ • Michael Toffler, DDS²
David M. Dohan Ehrenfest, DDS, MS, PhD³

Abstract



Choukroun's Platelet-Rich Fibrin (PRF) can be considered an autologous healing biomaterial, incorporating leucocytes, platelets and a wide range of key healing proteins within a dense fibrin matrix. With its strong fibrin architecture and slow release of growth factors and glycoproteins over several days, this natural bioactive membrane can enhance soft/hard tissues healing while protecting both surgical sites and grafted materials from external aggressions. In this article, we propose an overview of the use of PRF in post-

avulsion sockets or defects. PRF can be used as a filling material in avulsion (or extraction) sockets alone or mixed with a bone substitute. Used as a covering membrane for guided bone regeneration (GBR), PRF both protects the grafted material and accelerates wound closure, particularly when contiguous suture of the wound margins is not possible. The range of clinical applications of PRF is wide, but an accurate knowledge of the biomaterial, its biology, efficiency and limits is necessary to optimize its systematic use in daily practice.

KEY WORDS: Platelet rich fibrin, platelet rich plasma, autologous growth factors

1. Private Practice, Turin, Italy.

2. Private Practice, New York, NY, USA.

3. Researcher, Department of Biomaterials, Institute for Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

INTRODUCTION

The research and development of protocols promoting haemostasis and healing is a recurrent issue in all surgical disciplines. Fibrin is the first matrix in all wound healing processes,^{1,2} and the use of fibrin-based surgical additives, mainly fibrin glues, has a long history in oral and maxillofacial surgery.³⁻⁵ The evolution of these techniques resulted in the development of autologous fibrin glues and, since platelets contain a large amount of fibrinogen (the precursor of fibrin), to the concept of platelet concentrate for surgical use. Whitman et al⁶ first described the use of these platelets gels. Since the report by Marx et al,⁷ these products have been referred to as platelet-rich plasma (PRP), like the transfusional platelet concentrates from blood banks. Most authors refer to these products as a source of autologous growth factors. Unfortunately, the passion for growth factors has led to an underestimation of the function of leukocyte content and fibrin architecture in the healing equation.⁸

Since these early publications, a variety of autologous platelet concentrate techniques and devices have been developed, marketed and tested in a large number of clinical situations.⁹ In periodontal, implant and maxillofacial surgery, platelet concentrates were first used for their release of growth factors to stimulate the healing process. However, the clinical benefit is difficult to evaluate, and the literature is quite controversial on the subject.⁸ This is mainly due to the large number of techniques available, and to the absence of clear classification of the different products. Moreover, the PRP's were both expensive and time consuming protocols and their development in private practice remains quite limited. In 2001, a new protocol was sug-

gested in France by Choukroun et al¹⁰ to concentrate platelets and fibrin in a simpler way without blood modification: Platelet-Rich Fibrin (PRF).

DEFINITION OF PRF

PRF can be considered as an autologous healing biomaterial, incorporating in a matrix of autologous fibrin most leukocytes, platelets and growth factors harvested from a simple blood sample.¹¹⁻¹³ At the present time, the PRF protocol is both the most simple and inexpensive way to produce a platelet concentrate.⁸ The blood sample is drawn from the patient at the time of the surgical procedure and is treated with a single centrifugation, with a specific centrifuge (figure 1) and collection kit (Process, Nice, France), without blood manipulation: no anticoagulant during blood collection and no bovine thrombin or calcium chloride for fibrin polymerization.¹⁴ At the end of the centrifugation process, three distinct fractions are produced: 1) at the bottom of the tube, red cells are concentrated (and easily discarded); 2) the superficial layer is a liquid serum called platelet-poor plasma; 3) the intermediate fraction is a dense PRF clot, which can then be used clinically in the form of a membrane. The protocol requires a special tool (PRF box, Process, Nice, France) to prepare standardized membranes and to harvest PRF exudate, in a sterile environment (figures 2, 3).

Both PRF exudate and platelet-poor plasma contain significant amounts of growth factors (Transforming Growth Factors TGF β -1, Platelet-Derived Growth Factors PDGF-AB, Vascular Endothelial Growth Factors VEGF, etc)^{12,13} and matrix glycoproteins, particularly fibronectin and vitronectin. Fibronectin and vitronectin are two key proteins for cell-matrix contact; therefore,



Figure 1: PRF specific centrifuge.

using this exudate for biomaterial impregnation may be beneficial. With the PRF Box[®], PRF fibrin membranes are obtained with consistent size and thickness (figure 3). This tool is essential to guarantee objective and reproducible results.¹⁵

The PRF fibrin membrane is more elastic and consistent than the fibrin bulk sometimes obtained with some PRP protocols. PRP's are enhanced fibrin glues, and PRF is a true fibrin-based biomaterial⁸ which may be employed in many clinical situations.¹⁶⁻¹⁸ For example, its elasticity allows it to function as a suturable membrane. This biomaterial is both very easy and inexpensive to produce; therefore, its systematic use during oral and maxillofacial surgery must be considered a relevant clinical option. Moreover, it is completely autologous, so there is no ethical limitation or toxicity concerns related to this natural optimized blood clot.¹⁴




Figure 2: Using the PRF Box, PRF clots are collected and standardized.



Figure 3: After compression in the PRF Box, uniform PRF membranes are obtained.

PRF: AN AUTOLOGOUS BIOACTIVE MEMBRANE

Recently, a global classification of platelet concentrates was published, and these products are now classified in 4 families related to their leucocytes and fibrin contents.⁸ Choukroun's PRF is currently the sole product in the L-PRF class (Leukocyte and Platelet-Rich Fibrin), with both high leukocyte content and strong fibrin architecture. In addition, PRF membranes release high amounts of growth factors such as TGF β 1, PDGF-AB, VEGF and matrix glycoproteins (such as thrombospondin-1) during 7 days *in vitro*.¹⁹ The fibrin matrix with its intrinsic factors and leukocyte content contains the key ingredients for an enhanced healing of superficial

and bone tissues, particularly through the stimulation of neoangiogenesis. It was recently demonstrated in vitro that PRF enhances proliferation of many different cell types such as fibroblasts, osteoblasts, adipocytes, and keratinocytes.^{20,21} PRF also stimulates osteoblastic differentiation.²¹ The influence of leukocytes was already pointed out in this study, as these cells are true regulation turntables and produce large amounts of VEGF involved in angiogenesis.¹⁹ The PRF fibrin matrix as a filling biomaterial has produced consistently favorable clinical results.²²⁻²⁴ PRF, as an optimized blood clot, has also been shown to be a very efficient osteoconductive material in sinus-lifts.^{25,26}

The PRF protocol is finally a way to transform a natural blood clot into a clinically usable bioactive membrane. The synergetic effects of the fibrin matrix and its growth factor content lead to a natural and enhanced healing of soft and hard tissues. The platelet and leukocyte cytokines are gradually released during fibrin matrix physiological resorption,¹⁹ and matrix glycoproteins allow quick cell migration and proliferation within the PRF tissue-like architecture. This gradual release of cytokines appears to play a regulatory role in the inflammatory phenomena within the wounded tissues. However, the mechanical function of PRF must also be considered since the PRF membranes allow early wound protection and aid in primary soft tissue closure.^{17,18,27} This technique, which mimics the natural coagulation process, produces an inexpensive and simple bioactive membrane. Many researchers have tried to develop such membranes in artificial ways by incorporating growth factors in collagen membranes for example. This simple PRF technique produces the most natural bioactive product currently available.

USING PRF IN DAILY PRACTICE FOR POST-AVULSION SITES

The management of avulsion or extraction²⁸ sites is a daily issue since bone resorption following tooth removal can compromise both implantation and aesthetic results. For this reason, it is often recommended to insert a filling material inside the residual avulsion socket to maintain adequate bone volume. Many bone substitutes function primarily as a space-maintainer. However, these materials are often quite slow to resorb and remodel, and their use often delays the vascularization and bone regeneration at the site. In addition, the management of soft tissue over the graft requires flap release, extensive dissection, and vertical incisions in order to cover the grafted volume, reducing microvascularization at the margins. Used in this indication, PRF acts in the following ways as an optimized blood clot to enhance the natural healing process:

As a filling material in avulsion sockets,²² PRF will act as a stable blood clot for neovascularization and an accelerated tissue reconstruction (figures 4-8),² particularly in infected sites or in patients with medical conditions that may delay healing (eg. diabetes, immunosuppression). PRF stimulates both coagulation (with thrombospondin-1) and wound closure, making it a useful adjuvant in patients under anticoagulant therapies.

As a membrane for guided bone regeneration (GBR), the PRF dense matrix architecture covers, protects, and stabilizes the bone graft material and the operative site in general.¹⁷ Particularly, the elasticity and strength of the PRF fibrin membrane makes it easy to suture. When the socket is too wide for primary closure, the PRF fibrin matrix can be used as a covering and protective membrane that promotes re-



Figure 4: Avulsion/Extraction of tooth 15.



Figure 5: Preservation of site 15 with allograft.



Figure 6: Placement of PRF membrane. Primary closure not required.



Figure 7: Healing at 24 hours. The PRF membrane protects the socket and stimulates wound healing.

epithelialization of the site and accelerates the merging of the gingival margins (figures 9-22). However, in such circumstances, several PRF layers are required to adequately protect the grafted material and achieve the desired effect.

The mechanisms of these 2 common applications are in fact similar. Epithelial and connective tissue healing on PRF membranes is related both to the growth factors and the fibrin matrix.¹ Gingival fibroblasts easily migrate into this matrix and remodel it. The acceleration of the healing process makes the surgical site less sensitive to




Figure 8: Healing of site 15 at 15 days post-op.




Figure 9: Radiograph of fractured tooth 20.



Figure 10: Intraoral view of fractured tooth 20.




Figure 11: Tooth 20 was avulsed/extracted and immediately replaced with an implant (Intra-Lock, Boca Raton, FL, USA).




Figure 12: A cortico-spongy porcine bone (GenOs, Osteobiol, TecnoDental, Turin Italy) mixed with PRF was grafted in the defect.

aggressions (mechanical, bacterial and chemical) and thus positively influences both the aesthetic result and postoperative sensitivity. At a deeper level, PRF increases the cohesion between the graft materials as fibrin acts as a physiological glue between wounded tissues. Natural blood coagulation leads to the formation of a fibrin matrix that biologically links wounded tissues together allowing cell proliferation, cell migration, neomatrix

apposition and remodelling. Therefore, the combination of PRF with different kinds of filling materials should improve the integration of the grafted material, since PRF is an optimized blood clot.²⁵

However, even though these mechanisms are quite well known, the ideal application of PRF must still be accurately defined.¹⁵ The filling of avulsion sockets with PRF leads to very favourable results when the bony walls are intact. A combina-




Figure 13: PRF membrane used to cover graft.




Figure 14: Closure of surgical site with some PRF membrane exposed.



Figure 15: Healing at 3 months post-op.



Figure 16: Final implant supported prosthesis.




Figure 17: Pre-op view of hopeless tooth #30.




Figure 18: Resulting periodontal defect following removal of tooth #30.




Figure 19: Bone graft + PRF mixture added to site #30.




Figure 20: Graft covered with PRF membranes.



Figure 21: Mucoperiosteal flap closure.




Figure 22: Bone healing at 3 months.

tion of PRF with bone substitutes and other adjuvants may be necessary in residual defects where one or several walls are missing or damaged in order to predictably provide an adequate reconstitution of bone volume.^{17,18,29} In all cases, the systematic use of PRF leads, in our experience, to optimized gingival and bone regeneration which is particularly useful in implant site development.

CONCLUSIONS

The clinical benefits for the systematic use of PRF in daily practice are many. Inexpensive and simple to handle, this technique leads to

the production of a large quantity of bioactive autologous membranes with a powerful healing potential on both soft and hard tissues. Its range of clinical applications in oral and maxillofacial surgery is wide; as a filling material or protective membrane, and often as both. Used as a covering membrane, PRF accelerates healing and closure of the wound margins, stabilizes graft materials, and protects the surgical site from external aggressions. It generally provides a perceptible reduction in superficial tissue healing time, and patients often declare reduced postoperative pain. Mixed with graft material,

PRF will serve as biological cement between the particles and enhance neoangiogenesis and bone regeneration, particularly in stimulating osteoblastic proliferation and differentiation. However, this material is only an optimized and usable blood clot. Its potential applications are broad, but an accurate working knowledge of the biomaterial, its biology, efficiency and limits are necessary to optimize its use in daily practice. Therefore, additional studies evaluating the use and performance of PRF are warranted. ●

Correspondence:

David M. Dohan Ehrenfest
Department of Biomaterials,
Institute for Clinical Sciences,
The Sahlgrenska Academy at
University of Gothenburg,
Medicinaregatan 8B, 41390
Gothenburg, Sweden
e-mail: LoB5@mac.com

Disclosure

The authors report no conflict of interest with any products mentioned in this article.


References

- Clark RA. Fibrin and wound healing. *Ann NY Acad Sci* 2001; 936: 355-367.
- van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. *Ann NY Acad Sci* 2001; 936: 426-437.
- Matras H. Effect of various fibrin preparations on reimplantations in the rat skin. *Osterr Z Stomatol* 1970; 67(9): 338-359.
- Matras H. The use of fibrin sealant in oral and maxillofacial surgery. *J Oral Maxillofac Surg* 1982; 40(10): 617-622.
- Gibble JW, Ness PM. Fibrin glue: the perfect operative sealant? *Transfusion* 1990; 30(8): 741-747.
- Whitman DH, Berry RL, Green DM. Platelet gel: an autologous alternative to fibrin glue with applications in oral and maxillofacial surgery. *J Oral Maxillofac Surg* 1997; 55(11): 1294-1299.
- Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1998; 85(6): 638-646.
- Dohan Ehrenfest DM, Rasmusson L, Albrektsson T. Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF). *Trends Biotechnol* 2009; 27(3): 158-167.
- Dohan DM, Choukroun J. PRP, cPRP, PRF, PRG, PRGF, FC. How to find your way in the jungle of platelet concentrates? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 103(3): 305-306.
- Choukroun J, Adda F, Schoeffler C, Vervelle A. An opportunity in perio-implantology: the PRF (french). *Implantodontie* 2001; 42: 55-62.
- Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101(3): e37-44.
- Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101(3): e45-50.
- Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101(3): e51-55.
- Dohan DM, Del Corso M, Charrier JB. Cytotoxicity analyses of Choukroun's platelet-rich fibrin (PRF) on a wide range of human cells: The answer to a commercial controversy. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2007; 103(5): 587-593.
- Del Corso M, Sammartino G, Dohan Ehrenfest DM. Choukroun's Platelet-Rich Fibrin (PRF) membranes in periodontal surgery: understanding the biomaterial or believing into the magic of growth factors? *J Periodontol* 2009; In Press.
- Diss A, Dohan DM, Mouhyi J, Mahler P. Osteotome sinus floor elevation using Choukroun's platelet-rich fibrin as grafting material: a 1-year prospective pilot study with microthreaded implants. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; 105(5): 572-579.
- Simonpieri A, Del Corso M, Sammartino G, Dohan Ehrenfest DM. The relevance of Choukroun's platelet-rich fibrin and metronidazole during complex maxillary rehabilitations using bone allograft. Part I: a new grafting protocol. *Implant Dent* 2009; 18(2): 102-111.
- Simonpieri A, Del Corso M, Sammartino G, Dohan Ehrenfest DM. The relevance of Choukroun's Platelet-Rich Fibrin (PRF) and metronidazole during complex maxillary rehabilitations using bone allograft. Part II: implant surgery, prosthodontics and survival. *Implant Dent* 2009; 18(3): 220-229.
- Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. *Growth Factors* 2009; 27(1): 63-69.
- Choukroun J, Braccini F, Diss A, Giordano G, Doglioli P, Dohan DM. Influence of platelet rich fibrin (PRF) on proliferation of human preadipocytes and tympanic keratinocytes: A new opportunity in facial liposuction (Coleman's technique) and tympanoplasty? *Rev Laryngol Otol Rhinol (Bord)* 2007; 128(1-2): 27-32.
- Dohan Ehrenfest DM, Diss A, Odin G, Doglioli P, Hippolyte MP, Charrier JB. In vitro effects of Choukroun's PRF (Platelet-Rich Fibrin) on human gingival fibroblasts, dermal prekeratinocytes, preadipocytes and maxillofacial osteoblasts in primary cultures. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2009; In Press.
- Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101(3): e56-60.
- Braccini F, Dohan DM. The relevance of Choukroun's platelet rich fibrin (PRF) during facial aesthetic liposuction (Coleman's technique): preliminary results. *Rev Laryngol Otol Rhinol (Bord)* 2007; 128(4): 255-260.
- Charrier JB, Monteil JP, Albert S, Collon S, Bobin S, Dohan Ehrenfest DM. Relevance of Choukroun's Platelet-Rich Fibrin (PRF) and SMAS flap in primary reconstruction after superficial or subtotal parotidectomy in patients with focal pleiomorphic adenoma: a new technique. *Rev Laryngol Otol Rhinol (Bord)* 2008; 129(5): 313-318.
- Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part V: histologic evaluations of PRF effects on bone allograft maturation in sinus lift. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2006; 101(3): 299-303.
- Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, Dohan Ehrenfest DM. Sinus floor Augmentation With Simultaneous Implant Placement Using Choukroun's PRF (Platelet-Rich Fibrin) as sole grafting material: a radiological and histological study at 6 months. *J Periodontol* 2009; In Press.
- Saadoun AP, Touati B. Soft tissue recession around implants: is it still unavoidable?--Part II. *Pract Proced Aesthet Dent* 2007; 19(2): 81-87.
- Dohan Ehrenfest DM, Vazquez L. Pulling out, extraction or avulsion? *Implant Dent* 2008; 17(1): 4.
- Choukroun J, Simonpieri A, Del Corso M, Mazor Z, Sammartino G, Dohan Ehrenfest DM. Controlling systematic perioperative anaerobic contamination during sinus-lift procedures by using metronidazole: an innovative approach. *Implant Dent* 2008; 17(3): 257-270.


PRF[®] Platelet Rich Fibrin

- Leucocyte an Platelet Rich Fibrin Biomaterial
- Slow release of growth factors : > 7 days
- Automatic production of Fibrin Membranes rich in growth factors with the "PRF Box"
- The more easy and inexpensive system : < 1\$ for each membrane !
- Physiological acceleration of hard and soft tissue healing

PC 02



Clots in the PRF Box



PRF membranes




PRF membrane



PRF as filler in the socket extraction



Graft protection with PRF




Membrane under
schneiderian mucosa




Process, 49 rue Gioffredo - 06000 Nice - FRANCE
Phone +33 (0)4 93 85 58 90 - Fax +33 (0)957 333 256
www.prf-process.com




We invite you to take a *closer* look.




20,000,000X
Molecular Structure
Calcium Phosphate



200,000X
Ti Nano Structure



5,000X
Ti Micro Structure



100X
Ti Macro Structure


Better Ideas.



INTRA-LOCK
SYSTEM

www.intra-lock.com


THE ORIGINAL, PATENTED AND PROVEN DEVICE FOR PIEZOELECTRIC BONE SURGERY!



IMPLANT SITE PREPARATION



INTRAMURAL VESSEL PRESERVATION



RIDGE EXPANSION

EVIDENCE BASED

*12 Years Successful Clinical Research • 30+ US & International Patents
50+ Surgical Insert Tips • 80+ Published Articles & Studies*



Piezosurgery[®] Technology



Bone Bur



Bone Saw

Experience Piezosurgery[®]-schedule an appointment or in-office demo now!

CALL TODAY - 1.888.877.4396


www.piezosurgery.us

PIEZOSURGERY INCORPORATED

Ridge Split Technique Using Ultrasonic Surgical System: A Case Report

Kurt G. Hummeldorf, DMD¹ • Brian B. Chang, DMD² • Philip Vance, DMD³

Abstract



Background: Traditional methods of ridge augmentation to include bone grafting from various sources, which increases morbidity and time span for treatment. The ridge split technique may provide an alternative option for dental implant placement on an alveolar width deficiency.

Methods: A ridge split osteotomy was performed on bilateral mandibular edentulous sites using the VarioSurg® ultrasonic surgical system. The initial ridge expansion was obtained with osteotomes. This step was followed by an alternating sequence of manual delivery of

fixtures to gain additional alveolar expansion.

Results: Surgical treatment and implant placement were carried out without complications. Patient had uneventful follow ups and is pending osseointegration for prosthetic restoration.

Conclusions: A ridge split technique can provide the alveolar width increase needed for immediate implant placement in an atrophic mandibular ridge with a shorter treatment time and a successful and predictable outcome.

KEY WORDS: Ridge split, atrophic mandibular ridge, dental implant

1. Integrated Service Chief, Oral and Maxillofacial Surgery/Hospital Dentistry Service Walter Reed Army Medical Center and National Naval Medical Center
2. Chief Resident, Oral and Maxillofacial Surgery/Hospital Dentistry Service Walter Reed Army Medical Center and National Naval Medical Center
3. Senior Resident, Oral and Maxillofacial Surgery/Hospital Dentistry Service Walter Reed Army Medical Center and National Naval Medical Center

INTRODUCTION

Bone volume is crucial to placement of dental implants. Different techniques have been reported to improve on the inadequate bone volume often seen after dental extractions.¹ Guided bone regeneration, autogenous grafts, and alloplastic grafts are techniques to enhance bone volume, but these procedures add cost and require either increased healing time or additional surgical sites depending on the technique.² Split ridge techniques have advantages over other forms of maxillary and mandibular atrophic ridge augmentation. The split ridge technique allows for immediate placement of implants, shorter treatment time, and decreased cost.³ This technique heals similar to a socket and does not require a second surgical site; but like other ridge augmentation techniques, it is limited to increasing alveolar width and has limitations on vertical height.⁴ This report will show that with proper case selection and surgical design, a split ridge technique can provide the bone volume needed for implant placement in an atrophic mandibular ridge, with shorter treatment time and successful and predictable outcomes.

CASE REPORT

A 49-year-old active duty male presented to the National Naval Medical Center Oral and Maxillofacial Surgery clinic for implant evaluation. The patient was referred by a general dentist for bilateral mandibular fixed partial dentures (FPD) that were failing due to recurrent decay. Upon clinical and radiographic examination, the patient was diagnosed with bilateral acquired edentulism at sites 18-19, 30-31, and failing FPD's spanning 17-20 and 29-32. Due to his long history of edentulism, the patient had acquired



Figure 1: Presurgical radiograph.

atrophy of bilateral edentulous ridges. He had adequate vertical height but lacked width for implant placement. Various options of ridge augmentation were offered to the patient and the ridge splitting technique was chosen over other options of bone grafting to eliminate donor site morbidity and minimize treatment time.

The FPD's were sectioned and removed by a prosthodontist prior to the procedure. The patient was taken to the main operating room and general anesthesia was administered. After local anesthesia infiltrations on the right mandible, a crestal incision was made from the distal of site 29 to 32. A full thickness mucoperiosteal flap was elevated minimally buccally and lingually to preserve the periosteum. The atrophic ridge was identified and lack of width was noted. At this time, a prefabricated surgical guide was placed on the edentulous site and used to make an indentation on the alveolar ridge for planned implant placement. The malposed third molar was extracted at this time. Using the VarioSurg[®] ultrasonic surgical system, a mid-ridge osteotomy was made on the alveolar crest from mesial of site 29 to the extraction socket of tooth 32 connecting the indentations previously made with surgical guide. The



Figure 2: Partial edentulous left mandible.

osteotomy was made just through the cortex at the height of the alveolar crest. Next, the edentulous ridge was expanded with gradual osteotomes that are also used for sagittal split osteotomies. The planned implants to be used for the case were WP (5) x 13mm, tapered. Both sites were prepped with incremental drills up to RP (4) size. Also the depths were only drilled to about 2/3 of the bur, ~10mm. After making the osteotomies, two implants were then placed with 45N torque with approximately 1/3 of the fixtures engaged in




Figure 3: Surgical guide in place.

the mandible. Using the manual torque wrench, in alternating fashion, the fixtures were further driven into the osteotomy site. The torque wrench was advanced about 6 rotations per implant in alternating sequences to apply equal pressure in the osteotomy site and obtain even expansion. Demineralized freeze dried bone allograft (DFDBA) was placed into the extraction socket and expansion defect. Closure was performed in standard fashion. A similar procedure was carried out on the opposite side without placement of DFDBA.




Figure 4: Osteotome expansion of the edentulous ridge.




Figure 5: Osteotomy verification with direction indicators.




Figure 6: 5 x 13mm fixtures placed at 45N.

DISCUSSION

The ridge splitting technique is a viable alternative to other bone graft augmentation techniques. It has advantages over autogenous block grafting due to elimination of donor site morbidity and decreased treatment time. Requirements for the split ridge technique are: a) a ridge with deficient alveolar width but adequate bone height; b) appropriate interarch space; c) suitable amount of cancellous bone between cortical plates.⁵

The technique used in the procedure presented in this article is as described by Simion *et al.* in 1992 with modifications as described by Vercellotti in 2000 and by Coatoam and Mariotti in 2003.⁶⁻⁸ Simion introduced a split crest




Figure 7: Fixtures delivered and ridge expansion measured.

bone manipulation technique that created a greenstick fracture at the crest of the alveolus that would split the atrophic ridge into two parts allowing enough bone width for implant placement. Vercellotti successfully performed an entire edentulous ridge expansion of 3 mm using a modulated frequency piezoelectric energy scalpel. Coatoam and Mariotti reported good results in 500 cases starting in 1995 using split ridge techniques and heme-reconstituted demineralized freeze-dried bone (DFDBA).⁸ The technique employed in this article is a single staged implant approach where the fixture placement is used to simultaneously expand the ridge in a controlled fashion. Scipioni et al. reported 99% survival rates for 329 implants placed in 170 patients by using the one-stage immediate placement edentulous ridge expansion technique.⁹

While the split ridge technique does have advantages, it also has limitations. Intraoperative complications may include: a) intraoral instability of the dental implants; b) fracture of the alveolar ridge and compromised implant placement. After a dental extraction, the buccal ridge resorbs more than the palatal ridge, creating an




Figure 8: Mucosal closure.



Figure 9: Postsurgical radiograph.

ADVERTISE WITH JIACD

TODAY!

Reach more customers
with the dental
profession's first
truly interactive
paperless journal!

Using revolutionary online technology,
JIACD provides its readers with an
experience that is simply not available
with traditional hard copy paper journals.



WWW.JIACD.COM

increased likelihood that at the time of the split ridge technique the buccal plate will not be positioned appropriately, causing a compromised implant placement.¹⁰ Postoperatively, dehiscence of the buccal plate, crestal bone loss, soft tissue recession, and lack of osseointegration have been associated with the split ridge technique.¹¹ ●

Correspondence:

Dr. Kurt G. Hummeldorf
Oral and Maxillofacial Surgery, Building 9,
Deck 2
National Naval Medical Center
8901 Wisconsin Ave.
Bethesda, MD 20889-5600
Tel: 301-295-4340
Fax: 301-295-6075

Disclosure

The authors report no conflicts of interest with anything mentioned in this article.

Disclaimer

The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.

References

1. Elian N, Jalbout Z, Ehrlich B, Classi A, Cho S, et al. A two-stage full-arch ridge expansion technique: Review of the literature and clinical guidelines. *Implant Dent* 2008; (17)1: 16-20.
2. Adell R, Lekholm U, Rockler B, et al. A 15-year study of osseointegrated implants in the treatment of the edentulous jaw. *J Oral Surg* 1981; 10: 387-416.
3. Jemt T, Lekholm U, Adell R. Osseointegrated implants in the treatment of partially edentulous patients: A preliminary study on 876 consecutively placed fixtures. *Int J Oral Maxillofac Implants* 1989; 4: 211-217.
4. Summers R. The ridge expansion osteotomy. *Compend Contin Educ Dent* 1992; 12: 463-466.
5. Engelke W, Diederichs C, Jacobs H. Alveolar reconstruction with splitting osteotomy and microfixation of implants. *Int J Oral Maxillofac Implants* 1997; 12: 310-318.
6. Simion M, Baldoni M, Zaffe D. Jaw bone enlargement using immediate implant placement associated with a split-crest technique and guided tissue regeneration. *Int J Periodontics Restorative Dent* 1992; 12: 463-473.
7. Vercellotti T. Piezoelectric surgery in implantology: A case report – A new piezoelectric ridge expansion technique. *Int J Periodontics Restorative Dent* 2000; 20: 359-365.
8. Coatoam G, Mariotti A. The segmental ridge-split procedure. *J Periodontol* 2003; (74)5: 757-770.
9. Scipioni A, Bruschi G, Calesini G. Bone regeneration in the edentulous ridge expansion technique: Histologic and ultrastructural study of 20 clinical cases. *Int J Periodontics Restorative Dent* 1999; 19: 269-277.
10. Misch C. Implant site development using ridge splitting techniques. *Oral Maxillofac Surg Clin N Am* 2004; (16): 65-74.
11. Guirado J, Saez M, Carrion del Valle M, Zamora G. A maxillary ridge-splitting technique followed by immediate placement of implants: A case report. *Implant Dent* 2005; (14)1: 14-18.

Unbeatable experience and know-how...



IMPLANTCENTER
Piezo • Ultrasonic • Surgery & Implantology Unit



Placement



- Highest torque of any micro motor on the market
- Widest speed range on the market
- Compatible with all contra-angles

Preparation



- Selective cutting for preservation of soft tissue
- Accurate irrigation for prevention of bone overheating
- Handpiece does not overheat and is vibration free

Maintenance and more...



- Carbon fiber tips for safe maintenance of implants
- Diamond coated and bladed curette tips for perio treatments
- Color coding system for easy tip and power selection



ORAL CANCER STOPS HERE

Identafi® 3000 ultra: Shining an even brighter light on oral cancer detection

-  The ONLY Multi-Spectral device on the market
-  The ONLY oral cancer screening device utilizing 405nm
-  Double the autofluorescence power to ensure enhanced and thorough detection
-  Compact, Lightweight, Cordless, and Handheld device
-  Eliminates the need for messy, bad tasting dyes or solutions
-  Aids in determining the appropriate margin for surgical excision



TRIMIRA®
www.trimira.net

 visit us on Facebook
 @Identafi_3000

Upgrade your practice to *today's standard of care* for oral cancer detection.

For more information, simply call 1-888-984-9525, email us at info@trimira.net, or contact your local dental supplier.




Identafi®
3000
ultra

Identafi® 3000

Evaluation of Maxillary Osseous Lesion using CBCT in a Patient with Multiple Myeloma

Werner Harumiti Shintaku DDS, MS¹ • Marcel Noujeim DDS, MS²
Vidya Sankar DMD, MHS³

Abstract



Background: Multiple myeloma (MM) is a malignant disease that affects the skeleton and bone marrow. MM lesions can be found in bones of the head and neck which may be detected on intra and extra-oral radiographs.

Methods: On a periapical film taken in 2007, a 75-year-old male presented severe alveolar bone loss and a detached small bone fragment on the radicular distal aspect of tooth #11. The patient was diagnosed with MM in 2000. MM lesion was suspected and a cone-beam computed tomography (CBCT) was acquired.

Results: The findings were indicative of periodontal bone loss rather than a myeloma associated lesion, however other structures within the field-of-view could be assessed and previously undiagnosed MM lesions were detected.

Conclusions: Dentists play a vital role in the detection and diagnosis of suspicious imaging findings as they may indicate involvement or reactivation of MM. CBCT is a valuable tool in the care of these patients and the detection of new MM lesions underscores the necessity of all CBCT images to be verified by oral and maxillofacial (OMF) radiologists.

KEY WORDS: Multiple myeloma, imaging, cone-beam computed tomography, CBCT

1. Resident, Department of Diagnostic Science, The University of Texas Health Science Center at San Antonio Dental School, San Antonio, Texas, USA
2. Assistant Professor and Program Director, Department of Diagnostic Science, The University of Texas Health Science Center at San Antonio Dental School, San Antonio, Texas, USA
3. Assistant Professor, Oral Medicine, Department of Dental Diagnostic Science, The University of Texas Health Science Center at San Antonio Dental School, San Antonio, Texas, USA

BACKGROUND

Multiple myeloma (MM) is a clonal plasma cell malignancy and the most common primary malignancy to affect the skeleton and bone marrow. It accounts for approximately 1% of all cancers, more than 10% of hematologic neoplasms, and 43% of malignant bone tumors. The disease is most commonly found in males over 60 years old. Tumor infiltration is associated with cytokine production inducing increased osteoclastic bone resorption and decreased or absent osteoblastic activity. This process results in accelerated and imbalanced osteolysis of the bone frequently resulting in pathologic fractures, severe bone pain, hypercalcemia, and compression of vertebral bodies that compromises both quality of life and survival expectancy.^{1,2} Unfortunately, MM continues to be a severe life-threatening disease which is difficult to manage. Early detection and diagnosis of recurrent lesions are important for proper treatment and aids in prolonging survival rates.

Imaging plays a central role in the diagnosis, initial staging, follow-up, and restaging of patients with MM.³ Plain radiography and computed tomography (CT) are established imaging techniques for MM evaluation. Whole body screening using plain X-ray is still used in most newly diagnosed cases of the disease. Its sensitivity is high in established lesions and is used primarily in the diagnosis of vertebral compression. CT also has high sensitivity but availability, radiation dosage, and high cost are some disadvantages of the technique. In dentistry, cone-beam computed tomography (CBCT) is emerging as an acceptable alternative to CT due to its high sensitivity and specificity in detection of bone alterations and should be considered when following cases that involve the head and neck region.

This case report describes the potential application of CBCT in detecting oral bony lesions associated with MM or recurrent MM lesions.

CASE REPORT

A 75 year-old Caucasian male presented as a referral to the Tertiary Care Oral Medicine Clinic at the University of Texas Health Science Center at San Antonio (UTHSCSA) for evaluation of osteolytic lesions associated with the root of #11 detected on intraoral radiographic examination. The patient's medical history was significant for MM which was diagnosed in 2000. His symptoms at the time were episodes of back pain. The patient was treated with 4 cycles of chemotherapy (Mephalan and Interferon) and subsequent stem cell transplant. In 2001, Pamidronate Disodium and Zoledronic Acid were prescribed. He continued with Zoledronic Acid until 2006. At that time, his general dentist noticed exposed bone in the lower right quadrant, lingual to #30 and 31. The patient was referred to an oral surgeon for evaluation and treatment; the surgeon prescribed mouth rinses with Chlorhexidine and several months later there was healing of the region. Also during that time, the general dentist noted an endodontic lesion associated with #11 and root canal therapy was initiated. After treatment completion, the radiolucency on #11 persisted, prompting the referral to the oral medicine clinic at UTHSCSA.

At the time of our evaluation, the patient was taking Lenalidomide (10mg/day x 4 days), Enoxaparin (80mg), Dexamethasone (10mg/day x 5 days), Docusate, Acetaminophen, vitamins B, C, E, Zn and Folic Acid. The patient reported a previous history of melanoma, squamous and basal cell carcinomas of the skin, type 2 diabetes (when taking systemic steroids), and



Figure 1: Intraoral radiograph showing severe vertical alveolar bone loss and presence of a detached small bone fragment on the distal aspect of the root of the left maxillary canine.

slightly impaired kidney function. Lungs, liver, and gastrointestinal tract functions were within normal limits. The patient's social history revealed occasional alcohol use and no smoking or recreational drugs use were mentioned.

Upon clinical extraoral examination, the patient presented with multiple areas of scarring from the removal of basal and squamous cell carcinomas and the melanoma. There were no temporomandibular joint symptoms, thyromegaly, or lymphadenopathy. Intraorally, there was no evidence of exposed bone in the lower right quadrant. There was a 5-unit bridge extending from #11 to #15 and gingival recession extending from the middle of #10 to the distal of #11. The intraoral radiographs showed severe vertical alveolar bone loss and presence of a detached small bone fragment on the distal aspect of the root of #11 (figure 1). Due to the patient's medical history, MM involvement was suspected. In order to further evaluate the lesion, a CBCT was



Figure 2: Cone Beam reconstructed image allowing visualization of the extension and characteristics of the bone loss in the left maxillary canine area.

acquired (Alphard™ Asahi Roentgen, Japan). The cone beam images viewed with the 3D Ode-mand™ software (Cybermed, South Korea) allowed visualization without structural superimposition; the extension and characteristics of the bone loss could be determined and a periodontal bone loss pattern rather than a myeloma associated lesion was diagnosed (figure 2).

The acquired CBCT provided information on structures outside of the field-of-view (FOV) and revealed other previously undiagnosed sites in the calvarium (figure 3). Upon detection of these new lesions, the patient was informed of the findings and then referred to his oncologist for re-staging and follow-up of the disease.



Figure 3: Sagittal view showing other previously undiagnosed multiple myeloma sites (arrows) in the calvarium.

DISCUSSION

Multiple myeloma is a malignant clonal neoplasm of plasma cells of B-lymphocyte origin that commonly results in overproduction of large amounts of monoclonal immunoglobulins. According to Gonzales et al (1991), in 12 to 15% of MM cases reviewed by these authors, oral and maxillofacial manifestations were the first sign of disease.⁴ Common signs and symptoms include swelling, pain, mobility of teeth, bleeding, anaesthesia or paresthesia, pathological fracture, amyloid deposition, and soft tissue tumors.⁵ Seventy to 80% of patients with MM manifest some kind of bone involvement characterized mainly by osteolytic lesions.⁶ The multiple myeloma-induced osteolysis is a result of increased activity of osteoclasts adjacent to MM cells accompanied by suppressed osteoblastic differentiation and activity. Unlike oste-

olysis associated with other metastatic bone tumors, myeloma-associated lytic lesions are unique in that they do not repair even after many years of complete remission, reflecting a total loss of osteoblastic activity in areas of myeloma foci, apparently induced by the myeloma.⁷

Imaging plays an essential role in the assessment of skeletal involvement, detection of extramedullary diseases, and characterization of organ complications related to MM. Radiographic findings include “punched-out” radiolucencies without bone reaction, generalized osteoporosis, pathologic fractures and, occasionally, an osteosclerotic pattern.

Plain radiography is routinely used for skeletal surveys. Availability and low cost are some of the major advantages of conventional techniques. About 80% of patients with myeloma show radiographic evidence of skeletal involvement.⁸ However, the sensitivity of plain films may not be sufficient to detect early osteolytic lesions and evidence shows that CT presents higher diagnostic accuracy than plain films allowing for more precise exploration, and better management of this disease.⁹ Unfortunately, not all patients with MM have the proper access to advanced imaging modalities. D’Sa et al (2007) published an imaging guideline for cases of myeloma and questioned the utility of CT compared to plain films due to increased exposure to radiation and/or cost. The authors state that CT may not be practical as a screening tool; however it should be used to clarify the significance of ambiguous plain radiographic findings. CBCT may be a reasonable alternative in the head and neck region because it has the same ability to show early bone changes providing diagnostic images with lower radiation and cost in compar-

Table 1: Radiation effective doses to evaluate the maxillofacial region according to imaging modality

Imaging Modality	Effective Dose (E)
Two direct digital	0.0068 mSv
Large FOV CBCT¹¹	0.042 to 0.806 mSv
Computed tomography	1.7 to 4.9 mSv

ison with CT. Table 1 shows the necessary radiation effective dosage for each imaging modality applicable to evaluate the maxillofacial complex.

In the case presented here, CBCT was used to obtain more accurate information pertaining to the evaluation of the maxillary canine and supporting bone, as well as to access other structures of the head unattainable with conventional intraoral radiography. The images showed features characteristic of MM (bone defects and areas of osteoporosis) in places without any signs of symptoms reported by the patient, including the internal cortex of calvarium. CBCT images were useful to verify patient's current condition and presented several findings important and helpful in the medical management of the patient.

The purpose of imaging in the management of myeloma includes the assessment of the extent and severity of the disease at presentation, the identification and characterization of complications, and the assessment of response to therapy. Plain X-rays are routinely used for assessing dental and periodontal health; however, the compression into a two-dimensional image of a three-dimensional structure decreases both sensitivity and specificity

of the exam. CT is able to provide images in multiple plains allowing the assessment of areas that cannot be accurately visualized by plain radiography, but high radiation dosage and cost have always been a concern for this technique.

CBCT is a growing imaging modality and has been used to image the hard tissues of the maxillofacial region. This system is able to provide more information than any other conventional dental imaging modality with high diagnostic quality in short scanning time, lower radiation dosage compared to medical CT, and the ability to identify manifestations of the disease providing a more thorough examination of the patient. ●

Correspondence:

Werner H. Shintaku, DDS, MS
 The University of Texas Health Science Center
 at San Antonio
 Mail Code 7919
 7703 Floyd Curl Drive
 San Antonio, TX 78229-3900
 USA
 Telephone: +01-213-448-0255
 Fax: +01-210-567-3334
 e-mail: shintaku@uthscsa.edu

JIACD

The Journal of Implant & Advanced Clinical Dentistry

ATTENTION PROSPECTIVE AUTHORS JIACD wants to publish your article!

**For complete details
regarding publication in
JIACD, please refer
to our author guidelines at
the following link:**

**[http://www.jiacd.com/
authorinfo/
author-guidelines.pdf](http://www.jiacd.com/authorinfo/author-guidelines.pdf)**

or email us at:

editors@jicad.com

Disclosure

The authors report no conflicts of interest with anything mentioned in this article.

References

1. Garcia-Sanz R, Mateo MV, San Miguel JF. Multiple myeloma. *Med Clin (Barc)* 2007; 129(3):104-115.
2. Esteve FR, Roodman GD. Pathophysiology of myeloma bone disease. *Best Pract Res Clin Haematol* 2007; 20(4):613-624.
3. Mulligan ME. Imaging techniques used in the diagnosis, staging, and follow-up of patients with myeloma. *Acta Radiol* 2005; 46(7):716-24.
4. Gonzalez J, Elizondo J, Trull JM, De Torres I. Plasma-cell tumors of the condyle. *Br J Oral Maxillofac Surg* 1991; 29(4):274-276.
5. Scutellari PN, Orzincolo C. Mandibular lesions in multiple myeloma. *Radiol Med (Torino)* 1992; 83(3):219-223.
6. Callander NS, Roodman GD. Myeloma bone disease. *Semin Hematol* 2001; 38(3):276-285.
7. Epstein J, Walker R. Myeloma and bone disease: "the dangerous tango". *Clin Adv Hematol Oncol* 2006; 4(4):300-306.
8. D'Sa S, Abildgaard N, Tigh J, Shaw P, Hall-Craggs M. Guidelines of the use of imaging in the management of myeloma. *Br J Haematol* 2007; 137(1):49-63.
9. Ozaki S. Imaging techniques in multiple myeloma. *Nippon Rinsho* 2007; 65(12):2261-2267.
10. Gijbels F, Sanderink G, Wyatt J, Van Dam J, Nowak B, Jacobs R. Radiation doses of indirect and direct digital cephalometric radiography. *Br Dent J* 2004; 197(3):149-152.
11. Ludlow JB, Ivanovic M. Comparative dosimetry of dental CBCT devices and 64-slice CT for oral and maxillofacial radiology. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; 106(1):106-114.
12. Aldrich JE, Bilawich AM, Mayo JR. Radiation doses to patients receiving computed tomography examinations in British Columbia. *Can Assoc Radiol J* 2006;57(2):79-85.

SUNSTAR



GUIDOR®


*Matrix Barrier
is Back!*

An Engineered Synthetic Medical Device for Tissue Regeneration


• Most precise device since 1997 • Superior handling • Over 100 clinical studies

Unique Configurations for:


Guided Tissue Regeneration (GTR)



Perio Plastic Surgery (PPS)




Guided Bone Regeneration (GBR)




Case study by Dr. Gregory J. Conte, Periodontist, San Francisco, CA



Images 1-2: GUIDOR® Matrix Barrier to be placed on large circumferential osseous defects around maxilla right and mandible right second molars.



Images 3-4: Root surface modification and osseous distal around lower right second molar graft placed. The graft is covered and secured with a GUIDOR® wrap-around periodontal membrane. Suture allows for tight adaptation of the barrier membrane to the root surface.



Images 5-6: Flap adaptation and tension-free primary closure with interrupted Vicryl sutures.

Dr. Conte commented:
"I'm very pleased that the GUIDOR® product has returned to the U.S. market. This is the only resorbable barrier that I have worked with, that incorporates the many factors involved with the original concept of guided tissue regeneration."

To learn more about the relaunching of GUIDOR® Matrix Barrier: go to - www.guidor.com or call **1-877-GUIDOR1** (1-877-484-3671)

SUNSTAR



GUIDOR®

The PRECISION you require with the VERSATILITY you need

Radiosurgery® and its high frequency 4.0 MHz waveforms enable precise incisions with minimal thermal damage to surrounding tissue.


Learn how Radiosurgery® can help you generate revenue and expand your practice.



Dento-Surg™ Radiolase® II



Gingivectomy



Implant Exposure



Crown Preparation

Vist us at ellman.com to learn more about our patented technology for Dental procedures

Contact: TERRY GARDRVITS

Senior Sales Representative

Phone: (516) 267-6666

Cell: (516) 972-9048

Email: tgardrvits@ellman.com

Contact: SCOTT BERGER

Senior Sales Representative

Phone: (516) 267-6446

Fax: (516) 972-6447

Email: sberger@ellman.com

ellman® International, Inc.

3333 Royal Ave • Oceanside,

New York 11572-3625 • USA

(800) 835-5355 • (516) 594-3333

Successful Treatment Using Dental Implants in Patients with Systemic Sclerosis: A Report on Two Cases

**Mami Nakadai, DDS¹ • Hiroyasu Endo, DDS, PhD² • Terry D. Rees, DDS, MSD³
Hiroyuki Tamaki, DDS, PhD¹ • Hiroyuki Okada, DDS, PhD⁴
Takao Kato, DDS, PhD¹ • Hirotsugu Yamamoto, DDS, PhD⁴**

Abstract

Background: Systemic sclerosis (SSc) is a rare multisystem disease characterized by inflammation, vascular changes, and skin fibrosis. Orofacial abnormalities are frequently observed. Therapy for SSc patients is a challenge for dentists, as microstomia and xerostomia can make dental treatment complicated, while finger deformity due to sclerodactyly can make oral hygiene difficult for the patient. There are a few reports on implant treatment for SSc patients with fully edentulous jaws but none on implant placement for partially edentulous SSc patients.

Methods: We report on two limited cutaneous SSc patients treated with implant therapy for a partially edentulous jaw. A 66-year-old woman presented with loss of teeth #7 & 8, which had been extracted due to traumatic injury (Case 1). A localized ridge augmentation procedure was

performed, and two implants were placed. A 65-year-old woman presented with loss of tooth #28, which had been extracted due to dental caries (Case 2). One implant was placed.

Results: There were no postoperative complications after the ridge augmentation procedure was performed by block bone grafting (Case 1), implant placement, and implant second-stage surgery, which demonstrated normal wound healing. Osseointegration was favorably maintained for 5 years (Case 1) and 1 year (Case 2).

Conclusions: The injurious effect on osseointegration between the bone and implant in SSc patients is poorly understood. However, the use of implants for these patients may allow them to maintain their natural dentition for a long period of time, thus preventing fully edentulism.

KEY WORDS: Scleroderma, CREST syndrome, dental implants

1. Department of Oral and Maxillofacial Implantology, Nihon University, School of Dentistry at Matsudo, JAPAN
2. Department of Periodontology, Nihon University, School of Dentistry at Matsudo, JAPAN
3. Department of Periodontics, Baylor College of Dentistry, Texas A&M Health Science Center, Dallas, TX, USA
4. Department of Pathology, Nihon University, School of Dentistry at Matsudo, JAPAN

INTRODUCTION

Systemic sclerosis (SSc) is a rare multisystem disease characterized by inflammation, vascular changes, and skin fibrosis which generally begins after midlife and is more frequently seen in women.¹ Although the cause of SSc is unknown, the involvement of vascular endothelial cell changes and immunologic mechanisms inducing fibroblast activation has been speculated.²

SSc is suspected when skin sclerosis, especially in the region ranging from the fingertips to the upper and lower arms, is observed. The diagnosis of SSc is made on the basis of a skin biopsy and clinical findings.³ The histopathological findings of the disease show inflammatory and degenerative lesions in the connective tissues that are characterized by diffuse deposition of dense collagen.

SSc has two major variants, namely diffuse cutaneous SSc (DSSc) and limited cutaneous SSc (LSSc).³ Anti-Scl 70 (anti-topoisomerase I) antibodies appear in 23-75% of DSSc patients, while anti-centromere antibodies are found in 43-80% of LSSc patients.⁴ In DSSc patients, the skin sclerosis spreads to the trunk with visceral complications in the gastrointestinal tract, lungs, cardiovascular system and kidneys,⁴ while in LSSc, the skin sclerosis remains localized in the fingers and face. Furthermore, LSSc progresses more slowly than DSSc and these affected patients have a better prognosis. Patients having calcinosis, Raynaud's phenomenon, esophageal stricture, sclerodactyly and telangiectasia possess the clinical features constituting the CREST syndrome.

In SSc patients, orofacial abnormalities are frequently observed as facial skin sclerosis causes a mask-like face and microstomia.^{1,5-8} Most patients will have an interincisal distance

of less than 40 mm on maximum opening.⁶ The tongue becomes hard and rigid, making speaking and swallowing difficult. Xerostomia caused by fibrosis of the salivary gland or coexisting Sjögren's syndrome can induce a high incidence of dental caries and damage in the oral soft tissue. Telangiectasia of the oral mucosa is found in 56% of SSc patients,⁶ and the loss of the attached gingiva and multiple areas of gingival recession may occur in some patients.⁸ Furthermore, dental radiographic findings show a uniform widening of the periodontal ligament space in 10-37% of SSc patients⁷ and bone resorption in the mandibular angle, the condyle, coronoid process, or the posterior border of the ascending ramus in some patients.⁹

Accordingly, therapy for SSc patients is challenging for dentists, as microstomia and xerostomia can make dental treatment difficult, and finger deformity due to sclerodactyly may make oral hygiene hard for the patients to manage. As a result, treatment with a fixed prosthesis can easily lead to dental caries, and a removable prosthesis may be uncomfortable for the patient, frequently making it impossible to continue using it. As a result of complications in dental treatment, many SSc patients are often fully edentulous.¹⁰⁻¹⁷ There are few reports on implant treatment performed for fully edentulous SSc patients¹³⁻¹⁷ and, to the best of our knowledge, none on implant placement performed for partially edentulous SSc patients. Implant treatment for these patients may allow them to maintain their natural dentition for a long period of time, which may prevent the jaw from becoming fully edentulous. In this report, we present the cases of two LSSc patients treated with implant therapy for a partially edentulous jaw.



Figure 1: Sclerodactyly of the fingers in Case 1. A taut, shiny appearance of the skin is observed.




Figure 2: Limitation of mouth opening and telangiectasia of the lower lip (arrow) in Case 1. This photo demonstrates the patient's maximal opening because of the associated microstomia.




Figure 3: Telangiectasia of the palatal gingiva (arrow) in Case 1.




Figure 4: Panoramic radiograph before implant placement in Case 1.

CASE REPORT

Case 1

A 66-year-old woman was referred to us for implant therapy due to loss of teeth #'s 7 and 8 which had been extracted 1 year prior due to traumatic injury. Her case was complicated by Raynaud's phenomenon of the fingers for 10 years

and she was diagnosed with LSSc by a rheumatologist. Sclerodactyly was observed upon physical examination (figure 1) along with skin sclerosis around the mouth (figure 2). We measured her mouth opening using the technique according to Nagy et al.⁶, in which mouth opening of less than 40 mm is defined as "reduced." The maxi-



Figure 5: Localized deformity in an edentulous area of the anterior maxilla in Case 1 (mirror image). Occlusal view shows the extent of the bony ridge deformity.




Figure 6: Implant insertion 6 months after ridge augmentation procedure in Case 1.



Figure 7a: Intraoral view 5 years after implant placement in Case 1.

num mouth opening for this patient was 30 mm. In the oral mucosa, telangiectasia was observed in the lower lip, palatal gingiva, and mandibular facial gingiva (figures 2,3). She had 26 total teeth with teeth #'s 7 and 8 missing (figure 4). Mean probing depth was 2.5 mm and caries were not evident. Since she had been receiving periodic dental checkups, her oral hygiene was acceptable.




Figure 7b: Radiographic image 5 years after implant placement in Case 1.

The patient did not smoke or take any medications.

The alveolar ridge where the anterior teeth were missing was rated as Class H (horizontal) I (large) according to HVC ridge deficiency classification¹⁸ (figure 5). For the purpose of increasing the width of the alveolar ridge, a localized ridge augmentation procedure was performed prior to implant surgery. A block bone graft was collected from the chin, then positioned at the recipient site and retained with a bone screw under intravenous sedation with Midazolam. Six months after ridge augmentation, implant surgery was performed using a two-stage implant (Ankylos implant, DENTSPLY-Sankin K.K., Tokyo, Japan) under intravenous sedation with Midazolam. Two implants (3.5 mm diameter X 11 mm long) were placed (figure 6). Six months later a second-stage surgery was performed to fix the restoration. Periodic recall examinations were subsequently performed every 6 months. The radiographic findings 5 years later showed no peri-implant radiolucency and alveolar bone resorption was within a permissible limit (figure 7). There was no implant mobility suggesting that osseointegration was favorably maintained.

Case 2

A 65-year-old woman was referred to us for implant therapy due to the loss of tooth #28, which had been extracted 6 months prior due to dental caries. She had been diagnosed with LSSc by her physician 40 years before, then with type 2 diabetes mellitus and hypertension 15 years before, although the diseases had been favorably controlled. She was taking two medications (epalrestat and candesartan cilexetil) and she had no history of smoking. The mouth opening of this patient was 35 mm, demonstrating a mouth-opening reduction. Sclerodactyly was observed. There were no



Figure 8: Panoramic radiograph before implant placement in Case 2. The implant in the right mandibular area had been placed 3 years prior. There was no implant mobility.




Figure 9: Implant insertion in Case 2.




Figure 10: Radiographic findings 1 year after implant placement in Case 2.

changes found in the oral mucosa. She had 15 teeth and 1 implant, which had been placed for 3 years (figure 8). The mean probing depth was 2.4 mm. She had been receiving periodic dental checkups, thus her oral hygiene was acceptable.

For implant therapy, a two-stage implant (Ankylos implant, DENTSPLY-Sankin K.K., Tokyo, Japan) was used (3.5 mm diameter X 11 mm long), similar to that used in Case 1 (figure 9), although the second-stage surgery was performed 4 months after the first procedure to fix the restoration. Since the completion of this treatment, periodic recall examinations have been performed every 6 months. At the 1-year follow-up, the implant had clinically and radiographically osseointegrated (figure 10).

DISCUSSION

Implant failure can occur either as an early failure before and at about the time of abutment connection or as a later failure after implant loading.^{19,20} An early failure is caused by inadequate osseointegration between the bone and implant. When bone healing is disturbed for some reason, and osseointegration between the bone and implant is impaired after implant placement, scar tissue is

formed around the implant.²¹ As a result, it can become mobile and bone resorption may follow.¹⁹

Implant therapy may sometimes be contraindicated in patients with metabolic diseases such as diabetes mellitus and osteoporosis, and in immunocompromised patients, as it is thought that normal osseointegration may be impaired in those patients. However, the level of evidence of the latter is relatively low.²²⁻²⁵ Published case reports indicate that medically compromised patients such as those with Sjögren's syndrome,²⁶ severe lichen planus,²⁷ oral epidermolysis bullosa,²⁸ and Papillon-Lefevre syndrome²⁹ can be successfully treated with osseointegrated implants. However, implant therapy is likely contraindicated in patients with severe and acute medical conditions, and it is thought that the degree of disease control may be more important than the nature of the disease itself in regard to the effects on osseointegration. The two LSSc patients described in this report had no serious visceral lesion complications and relatively stable symptoms, which likely contributed to the success of implant therapy in these cases.

It is considered that anoxic tissue injury caused by prolonged vasospasms can lead to secondary fibrosis and scarring in SSc patients.^{2,4} At the sites of anoxic injury, T-cells, macrophages, and platelets are activated and release a variety of cytokines that are involved in the proliferation and differentiation of mast cells and fibroblasts. It is speculated that in SSc patients, these processes are accelerated to form dense scar formation which results in hypofunction of the skin and other internal organs.^{2,4} However, it is presently unknown whether or not pathologic changes in SSc patients may affect the osseointegration between the bone and implant or the wound healing of the bone.

There are 5 previous reports on implant ther-

apy performed for SSc patients, in which a total of 25 implants were placed.¹³⁻¹⁷ Among them, only 1 implant (7-mm implant) was removed due to a failure of osseointegration.¹⁷ There are also reports of reconstructive surgery for SSc patients, including corticocancellous grafting for treatment of osteomyelitis of the mandible³⁰ and surgical correction of secondary dysgnathia caused by SSc.⁹ In both of those reported cases, normal wound healing of the bone occurred.

Stanford et al.³¹ performed periodontal plastic surgery for a 38-year-old female with CREST syndrome and reported that the outcome of surgery was good without any surgical complications. They pointed out that telangiectasia was likely to cause excessive hemorrhaging in SSc patients and suggested considering the use of a surgical stent to deal with postoperative bleeding.³¹ In Case 1 described in this report, telangiectasia was observed in the palatal gingiva, mandibular facial gingiva and lower lip, although none was found around the site of implant insertion. Moreover, there were no postoperative complications after the ridge augmentation procedure performed by block bone grafting, implant placement, and implant second-stage surgery, which demonstrated normal wound healing.

A later-stage implant failure may be caused by peri-implantitis associated with plaque-related infection or occlusal overloading.^{19,20} There are contradicting reports regarding the susceptibility to periodontal infection in SSc patients. Wood & Lee⁵ reported that 31 patients with SSc had significantly more periodontal disease than the control subjects, as reflected by the increased pocketing and gingivitis scores and tooth mobility. The authors believed that reduced vascularity and tissue ischemia might explain the increased susceptibility to periodontal disease.⁵ In contrast, Nagy et

al.⁶ reported no significant differences in periodontal parameters including probing depth, gingivitis, plaque scores, and tooth mobility between 32 SSc patients and their matched healthy controls. In general, reduced mouth opening, tooth crowding and sclerodactyly often associated with SSc could interfere with effective oral hygiene and increase the risk for caries and periodontal disease. In the present study, the SSc patients had shallow mean probing depths and demonstrated no advanced chronic periodontitis. Furthermore, implant therapy was required for tooth loss due to traumatic injuries or dental caries, but not because of advanced periodontitis. Accordingly, in our patients, it cannot be said that the risk of peri-implant infection was high.

CONCLUSION

SSc patients are likely to be fully edentulous, and dental treatment is often difficult due to orofacial abnormalities. The injurious effect on osseointegration between the bone and implant in SSc patients is poorly understood, as there are no known reports on this subject. Nevertheless, implant therapy is likely to enhance the quality of life for SSc patients and may help them maintain long-term masticatory function. ●

Correspondence:

Dr. Mami Nakadai
 Dept. of Oral and Maxillofacial Implantology
 Nihon University School of Dentistry at
 Matsudo
 2-870-1 Sakaecho Nishi, Matsudo
 Chiba, Japan. 271-8587
 TEL: 81-47-360-9633
 FAX: 81-47-360-9621
 e-mail address: nakadai.mami@nihon-u.ac.jp

References

1. Albilal JB, Lam DK, Blanas N, Clokie CM, Sandor GK. Small mouths...Big problems? A review of scleroderma and its oral health implications. *J Can Dent Assoc* 2007;73(9):831-836.
2. Hawk A, English JC 3rd. Localized and systemic scleroderma. *Semin Cutan Med Surg* 2001;20(1):27-37.
3. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for scleroderma and sclerodermoid disorders. American Academy of Dermatology. *J Am Acad Dermatol* 1996;35(4):609-614.
4. Smiley JD. The many faces of scleroderma. *Am J Med Sci* 1992;304(5):319-333.
5. Wood RE, Lee P. Analysis of the oral manifestations of systemic sclerosis (scleroderma). *Oral Surg Oral Med Oral Pathol* 1988;65(2):172-178.
6. Nagy G, Kovacs J, Zeher M, Czirjak L. Analysis of the oral manifestations of systemic sclerosis. *Oral Surg Oral Med Oral Pathol* 1994;77(2):141-146.
7. Marmary Y, Glaiss R, Pisanty S. Scleroderma: oral manifestations. *Oral Surg Oral Med Oral Pathol* 1981;52(1):32-37.
8. Eversole LR, Jacobsen PL, Stone CE. Oral and gingival changes in systemic sclerosis (scleroderma). *J Periodontol* 1984;55(3):175-178.
9. Haers PE, Sailer HF. Mandibular resorption due to systemic sclerosis. Case report of surgical correction of a secondary open bite deformity. *Int J Oral Maxillofac Surg* 1995;24(4):261-267.
10. Yenisey M, Kulunk T, Kurt S, Ural C. A prosthodontic management alternative for scleroderma patients. *J Oral Rehabil* 2005;32(9):696-700.
11. Parel SM. Scleroderma: a prosthetic problem. *J Prosthet Dent* 1972;27(5):560-564.
12. Samet N, Tau S, Findler M, Susarla SM, Findler M. Flexible, removable partial denture for a patient with systemic sclerosis (scleroderma) and microstomia: a clinical report and a three-year follow-up. *Gen Dent* 2007;55(6):548-551.
13. Patel K, Welfare R, Coonar HS. The provision of dental implants and a fixed prosthesis in the treatment of a patient with scleroderma: a clinical report. *J Prosthet Dent* 1998;79(6):611-612.
14. Haas SE. Implant-supported, long-span fixed partial denture for a scleroderma patient: a clinical report. *J Prosthet Dent* 2002;87(2):136-139.
15. Raviv E, Harel-Raviv M, Shatz P, Gornitsky M. Implant-supported overdenture rehabilitation and progressive systemic sclerosis. *Int J Prosthodont* 1996;9(5):440-444.
16. Langer Y, Cardash HS, Tal H. Use of dental implants in the treatment of patients with scleroderma: a clinical report. *J Prosthet Dent* 1992;68(6):873-875.
17. Jensen J, Sindet-Pedersen S. Osseointegrated implants for prosthetic reconstruction in a patient with scleroderma: report of a case. *J Oral Maxillofac Surg* 1990;48(7):739-741.
18. Wang HL, Al-Shammari K. HVC ridge deficiency classification: a therapeutically oriented classification. *Int J Periodontics Restorative Dent* 2002;22(4):335-343.
19. van Steenberghe D, Jacobs R, Desnyder M, Maffei G, Quirynen M. The relative impact of local and endogenous patient-related factors on implant failure up to the abutment stage. *Clin Oral Implants Res* 2002;13(6):617-622.
20. Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (I). Success criteria and epidemiology. *Eur J Oral Sci* 1998;106(1):527-551.
21. Esposito M, Thomsen P, Ericson LE, Lekholm U. Histopathologic observations on early oral implant failures. *Int J Oral Maxillofac Implants* 1999;14(6):798-810.
22. Mombelli A, Cionca N. Systemic diseases affecting osseointegration therapy. *Clin Oral Implants Res* 2006;17 Suppl 2:97-103.
23. Beikler T, Flemmig TF. Implants in the medically compromised patient. *Crit Rev Oral Biol Med* 2003;14(4):305-316.
24. Scully C, Hobkirk J, Dios PD. Dental endosseous implants in the medically compromised patient. *J Oral Rehabil* 2007;34(8):590-599.
25. Hwang D, Wang HL. Medical contraindications to implant therapy: Part II: Relative contraindications. *Implant Dent* 2007;16(1):13-23.
26. Binon PP. Thirteen-year follow-up of a mandibular implant-supported fixed complete denture in a patient with Sjogren's syndrome: a clinical report. *J Prosthet Dent* 2005;94(5):409-413.
27. Esposito SJ, Camisa C, Morgan M. Implant retained overdentures for two patients with severe lichen planus: a clinical report. *J Prosthet Dent* 2003;89(1):6-10.
28. Penarrocha-Diago M, Serrano C, Sanchis JM, Silvestre FJ, Bagan JV. Placement of endosseous implants in patients with oral epidermolysis bullosa. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000;90(5):587-590.
29. Toygar HU, Kircelli C, Firat E, Guzeldemir E. Combined therapy in a patient with Papillon-Lefevre syndrome: a 13-year follow-up. *J Periodontol* 2007;78(9):1819-1824.
30. Ilacqua JA, Murphy JB. Management of osteomyelitis and nonunion of the mandible in a patient with progressive systemic sclerosis. *J Oral Maxillofac Surg* 1986;44(7):561-563.
31. Stanford TW Jr, Peterson J, Machen RL. CREST syndrome and periodontal surgery: a case report. *J Periodontol* 1999;70(5):536-541.

Redefining Perioplastic Surgery



See us at the
Accademy of
Osseointegration
Booth #101

SNOASIS
MEDICAL

Introducing...

 **BioCover™**

- The first membrane composed of allograft amnion tissue for use as a wound covering in the treatment of gingival recession.
- BioCover self-adheres to the surgical site eliminating the need for suturing thus reducing surgery time.
- BioCover can be conveniently stored at room temperature and possess a five year shelf life.
- For more information or to place an order visit:
www.snoasismedical.com



Before treatment



3 months post treatment

Case photographs courtesy of Dr. Brian Gurinsky, Denver, CO

BioCover™ is a trademark of Snoasis Medical, Inc.
©2008, All rights reserved.
Patents pending
010902

gIDE | UCLA 2009/2010 1 Year Master Program in Implant Dentistry

Two of the world's most respected education and academic organizations have joined forces to provide an innovative program

- Expert Faculty
- Live Surgery
- Case Presentations
- Hands-on
- 4 On-Site Sessions
- 90 Hours Self-Study



"Put on your seatbelt. This program dives right in, and immerses you into the world of dental implants, grafting and restorative excellence. No matter what your experience level is, you will gain confidence and improve your skills." - Dr. Jeffrey Rohde, Santa Barbara, CA , N. America Master Program 2008-2009

Main Program Objectives:



- A proven surgical and restorative implant program combining classroom, live patient, hands-on, case planning plus leading self-study online material
- Learn to perform new and routine implant procedures in minimal-invasive, efficient and cost-effective ways
- Learn advanced esthetic implant therapy, full mouth reconstruction, ridge and sinus bone grafting
- Graduate with 2 world-class Certificates from gIDE Institute and UCLA CED

Master Programs take place in several locations globally, see website for details



Los Angeles



Beijing



Taipei



Athens



Sydney

JIACD Continuing Education Factors Driving Peri-implant Crestal Bone Loss - Literature Review and Discussion: Part 3

**Mohammad Ketabi, DDS, MDS¹ • Robert Pilliar BSc, PhD²
Douglas Deporter, DDS, PhD³**

Abstract

Many factors contribute to the cumulative crestal bone loss seen around endosseous dental implants. This can create confusion for the practicing clinician and lead to undesirable outcomes. In this four part review series, we have searched the literature for

papers published in English language refereed journals for the decade preceding May 2008 and attempted to identify the major factors associated with peri-implant bone loss. Part three of this article series examines implant geometry, surface roughness, length, and diameter.

KEY WORDS: Crestal bone loss, dental implants, causative factors

Learning Objectives

After reading this article, the reader should be able to:

1. Discuss how implant geometry affects peri-implant crestal bone loss.
2. Discuss how implant neck design affects peri-implant crestal bone loss.
3. Discuss how implant surface roughness affects peri-implant crestal bone loss.
4. Discuss how implant length and diameter affects peri-implant crestal bone loss.

1. Dean, Professor and Chairman, Department of Periodontology, Faculty of Dentistry, Islamic Azad University (Khorasgan Branch), Arghavanieh, Isfahan, Iran
2. Professor Emeritus, Faculty of Dentistry & Center for Biomaterials, University of Toronto
3. Professor, Discipline of Periodontology and Oral Reconstructive Center, Faculty of Dentistry, University of Toronto

INTRODUCTION

Many factors, both biological and biomechanical, will have a cumulative impact on the final amount of bone loss seen with dental implants. It is important for clinicians to understand all of these factors in addition to their relative contributions and interactions. This is the third installment of a four part series reviewing factors that drive peri-implant crestal bone loss. Part one of this review examined surgical and anatomical factors associated with peri-implant crestal bone loss. Part two reviewed patient and biologic width factors while, the current installment of this series examines implant geometry, surface roughness, length, and diameter.

MATERIALS AND METHODS

A literature search of papers published in refereed journals in the English language for the decade preceding May 2008 was performed by computer using the National Library of Medicine and SCOPUS Cochrane Oral Health Group databases. Search strategy included a specific series of terms and key words. The reference lists of identified publications, relevant textbooks and professional workshops also were scanned.

Relevant references were selected on the basis of their titles and abstracts. As the final selection method, full texts of publications identified as possibly relevant were reviewed for more detailed evaluation. Publications reviewed included experimental animal studies, prospective and retrospective human clinical studies, a few case reports and relevant review papers. Because of the limited numbers of available studies for some factors and their heterogeneity, focusing on a specific pre-defined question to be answered

by a systematic review was not feasible and therefore no meta-analysis was attempted.

DISCUSSION

A number of dental implant related factors may contribute to peri-implant crestal bone loss. The most common of such factors include:

Implant geometry

Endosseous dental implants are essentially threaded screws made of titanium or one of its alloys (e.g. Ti-6Al-4V), although other implants such as plasma-sprayed surfaces press-fit cylinders and tapered truncated cones with porous surface zones formed by sintering Ti alloy powders also have been used.^{1,2} Until recently, the majority of threaded implants had a cylindrical (i.e. parallel-sided) shape. However, recently popular tapered shapes that more closely resemble tooth roots have been suggested to provide more optimal stress transfer into crestal bone.³ Following osseointegration, the bone-to-implant interface of most threaded implants comprises a planar contact without undercut regions. As a result, these transverse force components are transferred primarily as compressive forces to the crestal bone opposing the implant surface forced against it.⁴⁻⁷ Additionally, the resulting stresses will be greatest in bone next to the most coronal implant thread tips. The resulting high localized compressive stresses can lead to micro-fractures in crestal bone followed by resorption. This coincides with the fact that most crestal bone loss with traditional threaded implants occurs in the first year of function.

Ways to reduce the high compressive forces acting on crestal bone with threaded implant designs would be to use longer implants, wider

implants,⁸ specific thread pitch heights⁹ (especially in cancellous bone)⁹ tapered implant shapes, and micro-threads incorporated into the implant neck. Unlike most threaded implant designs, sintered porous-surfaced dental implants achieve integration by 3-dimensional bone ingrowth into and mechanical interlocking with the porous surface region formed by sintering. This type of bone-to-implant interface is able to provide resistance to interfacial tensile (upstream) forces. As a result, there is a more uniform stress distribution around the implant periphery with transverse force components being transferred to crestal bone at all implant aspects. This reduces the likelihood of micro-fracturing and resorption of crestal bone.^{2,4,5}

Implant neck design

Traditionally, the cervical or “neck” region of dental implants had a non-threaded, highly polished surface of sufficient height to accommodate biologic width without exposing much of the threaded implant segment meant to maintain implant fixation. Polished collar heights were generally in the range of 0.75 to 2.8mm. Remembering that establishment of biologic width required at least 1.5mm of linear implant surface from the micro-gap, polished collar height became more important with rough and moderately rough implant surfaces which ideally should remain buried in bone to avoid complications like peri-implantitis.¹⁰⁻¹³ Naturally, use of platform-switching to add a horizontal component to biologic width allows shorter polished collar regions to be used successfully. However, another effective way to manage the implant collar segment is to add micro-threads to its geometry.

Micro-threads offer two possible advantages. Firstly, their addition increases linear length of coronal implant surface available for biologic width and allows some stress transfer in the coronal region superior to the macro-threaded segment of implant body.¹⁴ This lower level of stress transfer to crestal bone is less likely to cause bone micro-fractures and reduces the probability for stress-shielding and disuse atrophy of crestal bone as may occur with traditional polished implant collars. Both clinical¹⁵⁻¹⁸ and animal¹⁹ studies have documented good retention of crestal bone for implants with incorporated micro-threads. In some studies, bone loss associated with coronally incorporated microthreads ranges from 0.11-0.18mm over 1 to 5 years.^{18,20,21} Finite element studies²² have suggested that creating laser micro-machined grooves (8 to 12 µm wide) to the lower part of a polished collar segment may reduce crestal bone loss in a manner similar to micro-threads (i.e. by altering strains in crestal bone) but, this possibility requires further study.

At present, few implant designs incorporate micro-threads. Rather, there has been a move to shorten or eliminate polished collar segments, with manufacturers electing to have implant collars with moderately rough surfaces in the hope of stimulating crestal bone with low levels of stress transfer as is thought to occur with micro-threads. This has not always been a successful approach as multiple studies have demonstrated increased crestal bone loss secondary to microbial colonization of exposed roughened collars.^{12,23-26}

While carrying a moderately rough texture all the way to the top of an implant has not been adequately confirmed to be beneficial, hav-

ing a polished collar that is too long also may lead to unwanted bone loss. Al-Sayyed et al²⁷ studied crestal bone loss in dogs around 2-piece, sintered porous-surfaced implants with either short (0.75mm) or long (1.8mm) collars. The short collared implants showed less bone loss, and the difference from long collared implants was linked to 'stress-shielding' of crestal bone and disuse atrophy.²⁸⁻³⁰ When histological preparations of retrieved specimens from Al-Sayyed's dog study were examined, the data suggested that the primary driving force in crestal loss seen was biologic width accommodation, not stress-shielding. Additional studies^{31,32} support the findings that the effect of stress-shielding with unnecessarily long polished collars is of relevance after biologic width accommodation has had its effect.

Implant surface roughness

Implant surface roughness may be classified as minimally rough, moderately rough, or rough. Machine-turned implant surfaces, as used on the original Branemark-system[®] threaded implant, are considered to be minimally rough (Sa - 0.5 μ m) while, only plasma-sprayed surfaces, like those used on the original Straumann ITI implant³³ or titanium plasma-sprayed press-fit implants,³⁴ are classified as rough (Sa > 2.0 μ m). The majority of contemporary threaded implant designs have what are considered to be moderately rough surfaces (Sa between 1.0 - 2.0 μ m). Moderately rough implant surfaces have been shown to be more osteoconductive than minimally rough ones³⁵ and, as a consequence, require shorter initial healing intervals.^{36,37} Employing a moderately rough surface increases resistance to torquing (i.e.

horizontal shear) forces once integration has developed^{38,39} and may be one approach to improving implant outcomes in bone of lower density even with abbreviated healing intervals.⁴⁰

Direct clinical comparisons of minimally rough (machine-turned) and rough (plasma-sprayed) threaded implants certainly have shown that the latter cause greater crestal bone loss and implant loss.^{10,11} However, data does not exist on whether incorporating features like minimally rough micro-threads in the collar region and platform-switching might make outcomes with rough surfaced implants more favorable. Certainly, rough surfaces on deeper threads could be of benefit as they provide highly irregular surfaces with undercut features that may allow sufficient mechanical interlock of bone to improve resistance to interfacial tensile forces associated with off-axis loading, at least compared to minimally and moderately rough surfaces.⁴

Direct clinical comparisons of minimally rough and moderately rough threaded implants have been accomplished. In multiple studies with long term follow-up intervals, moderately rough dental implant surfaces repeatedly demonstrated less crestal bone loss and higher survival rates in comparison to minimally rough implants.^{26,41-43}

Rocci and colleagues⁴⁴ compared anodized with machine-turned threaded implants that all were immediately loaded in posterior mandible locations. Implant failure rates were 14.5% for machine-turned and 4.5% for surface anodized implants. Mean marginal bone loss after 1 year of loading was similar (0.9 mm for surface anodized vs 1mm for machine-turned). Aalam et al¹² provided bone loss data for implants with surfaces roughened by anodization or dual acid-etching compared to machine-turned implants

at two years post-loading. No significant differences were seen but, a trend toward greater bone loss was seen with anodized implants which, as discussed earlier, unlike the other two implant types, had no polished collar. In contrast, Watzak et al⁶² reported significantly ($P=.03$) less marginal bone loss (1.17mm vs. 1.42mm) with anodized compared to machine-turned surfaces both of which had 1mm polished collars. These implants had been placed in the intra-foraminal region of edentulous mandibles and used to support overdentures during a mean functional period of 33 months.

Implant length and diameter

Both length and diameter (width) of dental implants may influence marginal bone loss. Naert et al²⁵ evaluated factors influencing marginal loss with machine-turned threaded implants functioning in partially edentulous patients for as long as 15 years. After 6 months in function, significantly ($P=.03$) more bone loss was observed as implant length increased. Implants in lengths of 7mm, 13mm, and 18mm had annual bone loss of 0.02mm, 0.04mm and 0.05mm respectively. It was suggested that longer implants lost more crestal bone because they were more likely to have been placed in sites of predominantly alveolar rather than basal bone, the latter being more resilient to resorption. However, other identified factors may have played a role in this rather surprising outcome. Rokni et al⁴⁵ reported a similar negative correlation between crestal bone loss and implant length with sintered porous-surfaced, press-fit implants after 5 years function. Long implants (9 or 12mm) had significantly greater crestal bone loss (0.2 mm more) than short implants (5 or 7mm). Others, however, have found that short threaded

implants suffer more crestal bone loss than longer ones. Chung et al⁴⁶ presented retrospective findings in 69 patients for 339 implants with various surface roughnesses. After an average of 8.1 years, implant length had a significant ($P<.05$) impact on bone loss with implants < 10 mm in length showing greater bone loss (0.19mm vs 0.12mm) than those with lengths ≥ 10 mm.

Like implant length, differing implant diameters have been associated with crestal bone loss. Multiple studies have demonstrated that increased implant diameter tends to be associated with reduced crestal bone loss.⁴⁷⁻⁵⁰ Studies^{47,48} using 3-dimensional finite element model analyses suggested a likely correlation between implant diameter and crestal bone loss with maximum stresses occurring around the implant neck and these stresses are likely to be reduced by increasing implant diameter. The greatest effect (31.5% reduction in stress) was found for increasing diameters from 3.6 to 4.2 mm. Moving to a 5.0mm diameter implant reduced stress by a lesser amount (16.4%).

CONCLUSIONS

Implant geometry will affect the type of bone-to-implant surface interface that is responsible for osseointegration. Most threaded implants achieve integration by planar bone-to-implant surface contact and this does not provide resistance to off-axis tensile forces. As a result, excessive compressive stresses can develop in bone abutting the tips of threads and lead to micro-fractures in crestal bone. Sintered porous-surfaced press-fit implants achieve integration by 3-dimensional interdigitation through bone ingrowth resulting in more uniform stress transfer and reduced likelihood of crestal bone micro-fractures and resorp-

tion. With threaded implants, ways to reduce high crestal stress concentration include using tapered rather than cylindrical implant shapes and/or incorporating micro-threads into the collar region of the implant body. These smaller threads are thought to promote more physiological crestal stresses resulting in crestal bone retention rather than resorption, as well as reducing peak stresses more apically (next to macro-threaded implant regions). In the absence of micro-threads and/or platform-switching, it is advisable that all dental implants have a short (e.g. 1 to 1.5mm) polished collar segment to allow for successful accommodation of biologic width without exposure of moderately rough or rough implant surfaces. Carrying these rough surfaces to the top of an implant body may in some situations increase the risk of excessive crestal bone loss and other complications.

The biggest impact of giving threaded implants a moderately rough texture is improvement in surface osteoconductivity and shortening of initial healing intervals. These surfaces do not appear to increase resistance to off-axis tensile forces. Because of the added surface area, however, moderately rough threaded implants often do appear to perform better than machined turned implants in bone of low density unless modified surgical procedures are employed to improve initial implant stability.⁵⁰

Finally, both implant length and diameter may affect crestal bone loss at least with some implant designs. Press-fit, sintered porous-surfaced implants for example show significantly less crestal bone loss in lengths of 5 or 7mm as opposed to lengths of 9 and 12mm. With threaded implant designs, study outcomes on the effects of implant length differ. Some investigators have reported greater crestal resorption as implant length increases and some the reverse relationship. Animal

and finite element analysis studies have suggested that as implant diameter increases crestal bone micro-fractures and resorption should decrease. ●

Professional Dental Education and Professional Education Services Group are joint sponsors with The Academy of Dental Learning in providing this continuing dental education activity.

The Academy of Dental Learning is an ADA CERP Recognized Provider. The Academy of Dental Learning designates this activity for two hours of continuing education credits.

ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

Correspondence:

Douglas Deporter, DDS, PhD
douglas.deporter@utoronto.ca

**FOR 2 HOURS CE CREDIT TAKE
THE QUIZ ON PAGE 72**



Disclosure

The authors report no conflicts of interest with anything mentioned in this article.

References

1. Pilliar R. Dental implants: Materials and design. *J Canadian Dent Assoc* 1990; 56: 857-861.
2. Pilliar R. Overview of surface variability of metallic endosseous dental implants: Textured and porous surface-structured designs. *Impl Dent* 1998; 7: 305-314.
3. Shi L, Li H, Fok A, Ucer C, Devlin H, Horner K. Shape optimization of dental implants. *Int J Oral Maxillofac Impl* 2007; 22: 911-920.
4. Pilliar R. Processing and properties of endosseous dental implant surfaces. Design for increased osseointegration potential. *Oral Health* 2000; August; 51-58.
5. Pilliar R, Sagals G, Meguid S, Oyonarte R, Deporter D. Threaded versus porous-surfaced implants as anchorage units for orthodontic treatment. Three-dimensional fine element analysis of peri-implant bone tissue stresses. *Int J Oral Maxillofac Impl* 2006; 21: 879-889.
6. Lin C-L, Wang J-C, Ramp L, Liu P-R. Biomechanical response of implant systems placed in the maxillary posterior region under various conditions of angulation, bone density and loading. *Int J Oral Maxillofac Impl* 2008; 23: 57-64.
7. Brink J, Meraw S, Sarment D. Influence of implant diameter on surrounding bone. *Clin Oral Impl Res* 2007; 18: 563-568.
8. Chung S, Heo S, Koak J, Kim S, Lee J, Han J, Han C, Rhyu I, Lee S. Effects of implant geometry and surface treatment on osseointegration after functional loading: A dog study. *J Oral Rehab* 2008; 35: 229-236.
9. Kong L, Hu K, Li D, Song Y, Yang J, Wu Z, Liu B. Evaluation of the cylinder implant thread height and width: A 3-dimensional finite element analysis. *Int J Oral Maxillofac Impl* 2008; 23: 65-74.
10. Becker W, Becker B, Ricci A, Bahat O, Rosenberg E, Rose L, Handelsman M, Israelson H. A prospective multicenter clinical trial comparing one- and two-stage titanium screw-shaped fixtures with one-stage plasma-sprayed solid-screw fixtures. *Clin Oral Impl Rel Res* 2000; 2: 159-165.
11. Astrand P, Engquist B, Ansen B, Bergendal T, Hallman M, Karlsson U, Kvint S, Lysell L, Rundcranz T. A 3-year follow-up report of a comparative study of ITI dental implants & Branemark system implants in the treatment of the partially edentulous maxilla. *Clin Impl Dent Rel Res* 2004; 6: 130-141.
12. Aalam A-A, Nowzari H. Clinical evaluation of dental implants with surfaces roughened by anodic oxidation, dual acid-etched and machined implants. *Int J Oral Maxillofac Impl* 2005; 20: 793-798.
13. Ostman P, Hellman M, Albrektsson T, Sennerby L. Direct loading of Nobel Direct® and NobelPerfect® one-piece implants: A 1-year prospective clinical & radiographic study. *Clin Oral Implant Res* 2007; 18: 409-418.
14. Hansson S. The implant neck: Smooth or provided with retention elements. A biomechanical approach. *Clin Oral Impl Res* 1999; 10:394-405.
15. Karlsson U, Gotfredsen K, Olsson C. Single-tooth replacement by osseointegrated Astra Tech dental implants: A 2-year report. *Int J Prosthodont* 1997; 10: 318-324.
16. Norton M. Marginal bone levels at single tooth implants with a conical fixture design. The influence of surface macro and micro structure. *Clin Oral Impl Res* 1998; 9: 91-99.
17. Palmer R, Palmer P, Smith B. A 5-year prospective study of Astra single tooth implants. *Clin Oral Impl Res* 2000; 11:179-182.
18. Wennström J, Ekestubbe A, Gröndahl K, Karlsson S, Lindhe J. Implant-supported single-tooth restorations. A 5 year prospective study. *J Clin Periodont* 2005; 32:567-574.
19. Abrahamsson I, Berglundh T. Tissue characteristics at micro-threaded implants: An experimental study in dogs. *Clin Impl Dent Relat Res* 2006; 8 :107-113.
20. Shin Y, Han C, Heo S, Kim S, Chun H. Radiographic evaluation of marginal bone level around implants with different neck designs after 1 year. *Int J Oral Maxillofac Impl* 2006; 21: 789-794.
21. Lee D, Choi Y, Park K, Kim C, Moon I. Effect of micro-thread on the maintenance of marginal bone level: A 3-year prospective study. *Clin Oral Impl Res* 2007; 18: 465-470.
22. Alexander H, Ricci J, Hrico G. Mechanical basis for bone retention around dental implants. *J Biomed Mater Res Part B: Appl Biomater* 23 April 2007; Early view: published online; © 2007 Wiley Periodicals Inc.
23. Sennerby L, Rocci A, Becker W, Jonsson L, Johansson L, Albrektsson T. Short-term clinical results of Nobel Direct implants: A retrospective multicenter analysis. *Clin Oral Impl Res* 2008;19:219-226.
24. Alomrani A, Hermann J, Jones A, Buser D, Schoolfield J, Cochran D. The effect of a machined collar on coronal hard tissue around titanium implants: A radiographic study in the canine mandible. *Int J Oral Maxillofac Impl* 2005; 20: 677-686.
25. Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on bio-film development. *Clin Oral Impl Res* 2006; 17 (Suppl. 2): 68-81.
26. Zechner W, Trinki N, Watzek G, et al. Radiographic follow-up of peri-implant bone loss around machine-surfaced and rough-surfaced interforaminal implants in the mandible functionally loaded for 3 to 7 years. *Int J Oral Maxillofac Impl*. 2004;19: 216-222.
27. Al-Sayyed A, Deporter DA, Pilliar RM, Watson PA, Pharoah M, Berhane K, Carter S. Predictable crestal bone remodelling around two porous-coated titanium alloy dental implant designs. A radiographic study in dogs. *Clin Oral Impl Res* 1994;5:131-41.
29. Pilliar RM, Deporter DA, Watson PA, Valiquette N. Dental implant design – Effect on bone remodeling. *J Biomed Mater Res* 1991;25:467-483.
30. Vaillancourt H, Pilliar RM, McCammond D. Factors affecting crestal bone loss with dental implants partially covered with a porous coating. A finite element analysis. *Int J Oral Maxillofac Impl* 1996;11:351-359.
31. Wiskott H, Belser U. Lack of integration of smooth titanium surfaces: A working hypothesis based on strains generated in the surrounding bone. *Clin Oral Impl Res* 1999;10:429-444.
32. Hänggi M, Hänggi D, Schoolfield J, Meyer J, Cochran D, Hermann J. Crestal bone changes around titanium implants. Part I: A retrospective radiographic evaluation in humans comparing two non-submerged implant designs with different machined collar lengths. *J Periodont* 2005; 76: 791-802.
33. Schwarz F, Herten M, Bieling K, Becker J. Crestal bone changes at non-submerged implants (Camlog) with different machined collar lengths: A histomorphometric pilot study in dogs. *Int J Oral Maxillofac Impl* 2008; 23: 335-342.
34. Buser D, Schroeder A, Sutter F, Lang N. The new concept of ITI hollow-cylinder and hollow-screw implants: Part 2. Clinical aspects, indications and early clinical results. *Int J Oral Maxillofac Impl* 1988; 3: 173-182.
35. Babbush C, Kirsch A, Mentag P, Hill B. Intramobile cylinder (IMZ) two-stage osseointegrated implant system. Part I: Its rationale and procedure for use. *Int J Oral Maxillofac Impl* 1987; 2: 203-216.
36. Davies J. Understanding peri-implant endosseous healing. *J Dent Educ* 2003; 67: 932-949.
37. Cochran D, Buser D, ten Bruggenkate C, Weingart D, Taylor T, Bernard J-P, Peters F, Simpson J. The use of reduced healing times on ITI® implants with a sand-blasted and acid-etched (SLA) surface: Early results from clinical trials on ITI® SLA implants. *Clin Oral Impl Res* 2002; 13: 144-153.
38. Testori T, Del Fabbro M, Feldman S, Vincenzi G, Sullivan D, Rossi R, Anitua E, Bianchi F, Francetti L, Weinstein R. A multi-center prospective evaluation of 2-months loaded Osseotite® implants placed in the posterior jaws: 3-year follow-up results. *Clin Oral Impl Res* 2002; 13: 154-161.
39. Buser D, Nydegger T, Hirt H, Cochran D, Nolte L-P. Removal torque values of titanium implants in the maxilla of miniature pigs. *Int J Oral Maxillofac Impl* 1998; 5: 611-619.
40. Klokkevold P, Johnson P, Dadgostari S, Davies J, Caputo A, Nishimura R. Early endosseous integration enhanced by dual acid etching of titanium: A torque removal study in the rabbit. *Clin Oral Impl Res* 2001; 12: 350-357.
41. Rocuzzo M, Wilson T. A prospective study evaluating a protocol for 6 weeks' loading of SLA implants in the posterior maxilla. One-year results. *Clin Oral Impl Res* 2002; 13: 502-507.
42. Astrand P, Engquist B, Dahlgren S, Engquist E, Feldmann H, Gröndahl K. Astra Tech and Branemark System Implants: A Prospective 5-Year Comparative Study. Results after one year. *Clin Oral Dent Rel Res* 1999; 1: 17-26.
43. van Steenberghe D, De Mars G, Quirynen M, Jacobs R, Naert I. A prospective split-mouth comparative study of two screw-shaped, self-tapping pure titanium implant systems. *Clin Oral Impl Res* 2000; 11: 202-209.
44. Hallman M, Mordenfeld A, Strandkvist T. A retrospective 5-year follow-up study of two different titanium implant surfaces used after inter-positional bone grafting for reconstruction of the atrophic edentulous maxilla. *Clin Impl Dent Rel Res* 2005; 7: 121-126.
45. Rocci A, Martignoni M, Gottlow J. Immediate loading of Brånemark System Ti-Unite and machined-surface implants in the posterior mandible: A randomized open-ended clinical trial. *Clin Impl Dent Rel Res* 2003; 5 (Suppl 1) :57-63.
46. Rokni S, Todescan R, Watson P, Pharoah M, Adegbembo A, Deporter D. An assessment of crown-to-root ratios with short sintered porous-surfaced implants supporting prostheses in partially edentulous patients. *Int J Oral Maxillofac Impl* 2005; 20: 69-76.
47. Chung D, Oh T-J, Lee J, Misch C, Wang H-L. Factors affecting late implant bone loss: A retrospective analysis. *Int J Oral Maxillofac Impl* 2007; 22: 117-126.
49. Iplikcioglu H, Akca K. Comparative evaluation of the effect of diameter, length and number of implants supporting three-unit fixed partial prostheses on stress distribution in the bone. *J Dent* 2002; 30: 41-46.
50. Himmlova L, Dostalova T, Kacovsky A, Konvickova S. Influence of implant length and diameter on stress distribution: A finite element analysis. *J Prosthet Dent* 2004; 91: 20-25.
51. Degidi M, Piattelli A, Iezzi G, Carinci F. Immediately loaded short implants: analysis of a case series of 133 implants. *Quintess Int* 2007; 38:193-201.
52. Martinez H, Davarpanah M, Missika P, Celletti R, Lazzara R. Review article: Optimal implant stabilization in low density bone. *Clin Oral Impl Res* 2001; 12: 423-432.

Continuing Education JACD Quiz #5

1. Most crestal bone loss associated with dental implants happens when?

- a. Within first year of function
- b. Between years 2-3 of function
- c. Between years 3-5 of function
- d. After 10 years of function

2. Ways to reduce compressive forces acting on crestal bone include:

- a. Using longer implants
- b. Using wider implants
- c. Using tapered implant shapes
- d. All of the above

3. To avoid complications such as peri-implantitis, roughened implant surfaces should ideally remain buried in bone.

- a. True
- b. False

4. What advantages are offered by a micro-threaded collar design?

- a. Increase linear length of coronal implant surface available for biologic width
- b. Allows stress transfer in the apical region superior to the macro-threaded segment of implant body
- c. There are no advantages offered by micro-threads
- d. All of the above

5. Over one to five years, what is the range of bone loss associated with coronal micro-threads?

- a. 0.11 – 0.18mm
- b. 0.25 – 0.50mm
- c. 0.51 – 0.76mm
- d. 1.09 – 1.6mm

6. Implant surface roughness may be classified as:

- a. Minimally rough
- b. Moderately rough
- c. Rough
- d. All of the above

7. The majority of contemporary threaded implant designs have what type of surface?

- a. Minimally rough
- b. Moderately rough
- c. Rough
- d. Smooth

8. Moderately rough implant surfaces have been shown to be more osteoconductive than minimally rough implant surfaces.

- a. True
- b. False

9. In multiple studies with long term follow-up intervals, which implant surfaces repeatedly demonstrated less crestal bone loss and higher survival rates?

- a. Smooth
- b. Minimally rough
- c. Moderately rough
- d. Rough

10. 3D finite element models suggest that maximum stress occurs at what portion of the implant?

- a. Implant neck
- b. Implant body
- c. Implant apex
- d. Stresses are uniformly distributed

CLICK HERE TO TAKE THE QUIZ



WESTPORT MEDICAL POWERTOME 100S

*save bone
save time*

THE POWERTOME™ *the extraction advantage™ for surgeons and patients*

The Powertome™ improves the tooth removal process for both surgeons and patients by providing greater control for the surgeon during extractions. The Powertome™ is an automated periosteal separator that offers extremely precise tooth extraction with minimal or no alveolar bone loss. The surgery is often flapless so patients experience reduced pain and swelling. This translates into less chair time and faster recovery for the patient.



The hand held device is designed to be very similar to footswitch activated, dental hand pieces, so the operation, actuation, and sterilization are therefore intuitive. Our technology gives extremely sensitive tactile feedback to the practitioner.

- Reduces bone loss in extractions.
- Increases efficiency in extractions.
- Allows for an immediate implant after an extraction.
- A quick release chuck allows rapid tip replacement.
- Handpiece and tips are fully autoclaveable.
- Innovative design reduces hand fatigue.
- UL-60601 tested.



hand held device



minimum bone loss

ISTM 2010

Comprehensive Surgery Training For

Back by Popular Demand
Regenerative
Technologies
Forum


Novice and Experienced Implant Surgeons

Presented by

Dr. Anthony G. Sclar

Author of:

*Soft Tissue and Esthetic Considerations
In Implant Therapy*



**February 19-23, 2010
Miami Beach, Florida**

**Flexible 3-day, 4-day, or 5-day program options
allow you to customize your learning experience!**

DAY 1: Essentials of Implant Surgery

DAY 2: Soft Tissue Grafting - Oral-Plastic Surgery - Soft Tissue Site Development

DAY 3: Intra-Oral Bone Grafting and Hard Tissue Site Development

DAY 4: Demystifying Esthetics Implant Therapy

DAY 5: Avoiding and Managing Complications in Implant Therapy



Details on: www.sclarcenter.com

"All serious implant surgeons, whether a beginner or a veteran, should take this course. It's structure and content provide you with the tools to deliver a higher standard of care for your patients. Thank you for raising the bar!"

Dr. Tom Stevenson, OMS, Edmonton, Canada

"ISTM is an excellent balance of scientific and clinical practice. Evidence based practice protocols presented in an passionate informative and entertaining way. Concepts were reinforced superbly with the blend of didactic, video presentation and workshops."

Dr. Brian Whitley, OMS, Hamilton, New Zealand



straumann

BIOMET 3i

**Nobel
Biocare**

**THOMMEN
Medical**

**PHILIPS
sonicare**
the sonic toothbrush

Osteohealth®
REVOLUTIONIZING REGENERATION™

Hu-Friedy

**Imaging
Sciences
International**

SALVIN®
Dental Specialties

Is Your Website Alive?

A BEAUTIFUL, LIVING, BREATHING WEBSITE
ATTRACTS YOUR IDEAL PATIENTS




A static, lifeless website is dead in the eyes of search engines and rarely attracts new patients. To breathe new life into your website you must take advantage of the latest tools the web has to offer.

Our marketable websites include:

- Fresh and unique website content that motivates your visitors to pick up the phone and call you first.
- A beautiful gallery of before & after photos of your patients.
- Video that builds trust and connects emotionally with your visitors using testimonials, interviews and our new powerful online video consultation.

Every site is engineered for Search Engine Optimization (SEO). Your new beautiful Flash website contains a blend of just the right amount of HTML so that you are listed prominently in the search engines.



Call us for a FREE Online Marketing Analysis and see just how many patients are searching for your practice right now.

CALL US NOW AT **888.728.4184**



roadside MULTIMEDIA | MARKETING

www.roadsidemultimedia.com

What's the real cost of your system?

The Facts on Platelet Rich Plasma Devices

The SmartPReP® 2 Platelet Concentrate System has been used in more than 200,000 surgical* procedures.



As clinicians, it can be difficult to separate fact from fiction, but at Harvest, the proof is in the product. The SmartPReP 2 produces viable platelets increased 4X or greater above baseline levels: the clinical requirements needed to accelerate wound healing.

*The Harvest Technologies PRP Separation System is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small amount of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.

HARVEST® 40 Grissom Rd., Ste. 100, Plymouth, MA 02360
877.8.HARVEST ~ www.harvesttech.com

Developing Technologies for Accelerating Healing, Naturally



Platelet Yield

The SmartPReP 2 patented floating shelf technology optimally separates biological cellular components; producing platelet yields 4-6x above baseline levels.




Technologist Time

The SmartPReP 2 produces autologous platelet concentrate in a fraction of the time as other systems; requires only 2-3 minutes hands-on technologist time.



Sterile Barrier Entries

The SmartPReP 2 has the fewest sterility breaks of any system; this decreases the risk for mistakes or contamination.



Growth Factors

The SmartPReP 2 produces consistent levels of platelet concentrate with 7 growth factors, fibrin, fibronectin and vitronectin.



FDA Cleared

The SmartPReP has been in use for over 8 years in US for the preparation of autologous PRP. Is your machine's PRP cleared for human use?

For copies of the test results on Harvest SmartPReP 2 compared to other PRP system done by the Center for Blood Research at Harvard email kjames@harvesttech.com

The Future is **NOW**

Join the 21ST century
with the only lab prepared
to take on the ever-evolving
technologies of the future.

**Are you able to offer your patients the latest
dental restorations and systems?
Is your lab up to date with new technology?**

For more than 35 years, Marotta Dental Studio has been working with the restorative dentist, prosthodontist, periodontist and oral surgeon as a team, providing precision-crafted prosthetics, superb esthetics and personalized service.

We have been and still are the Beta lab for new technologies and concepts for every branch of dentistry. We were instrumental in the development of the Procera[®] implant bridge, Encode, NobelGuide[™], Procera[®], Lava[™], CAM StructSURE[®], Implant restorations, Easy Guide, Inter oral scanning and digital impression taking, digital shade taking, custom surgical drill guides, bonding cements for zirconia, blasting compounds on zirconia, frames designs for implants and esthetics restorations, a line of patented implant components sold through various suppliers, Zirconia innovations, Pressed-to ceramics, Simplant surgical guides, Synthetic porcelain, Nitrogen processed provisional, immediate load technologies, milled titanium, cast titanium Cad/Cam technologies such as Stereolithography, wax printing and milling, as well as many more research projects and case studies too numerous to mention and all **made in America**.

Our goal is to produce the finest quality dental prosthetics while maintaining a supportive environment for both our employees and our clients. We promote a family atmosphere that includes an emphasis on service, support, and education.

We have the best trained, most reliable, most experienced, elite team of Dental technicians in the world. **All performed in The U.S.A.**



MAROTTA

Where Dentistry is Art

MarottaDental.com

1-866-Marotta (627-6882)

Are you getting what
you need from your current
allograft implant provider?

www.OraGraft.com

The Ultimate Hands On Live Patient Course You Have Been Waiting For



Next
Available Dates:
April 22nd-25th 2009
July 1st-4th 2009
November 4th-7th 2009
March 24th-27th 2010

There are numerous implant hands-on courses for clinicians focusing on model training or sometimes a cadaver workshop trying to simulate the human oral cavity.

Occasionally lack of experience makes the transformation of the surgical techniques to our patients difficult.

For the first time the international course for oral implantology allows the clinician to perform on patients a variety of dental implant surgical procedures including sinus augmentations and immediate loading procedures in cases with single, partial and complete edentulism. All of the above will be performed under the close supervision of some of the leading well experienced clinicians:

Dr Ziv Mazor, Dr Adi Lorean, Dr Eitan Mijiritsky & Prof Voya Lekovic.

The program allows one-on-one interaction between the participant and the instructor. In the Implant beginner course each participant places at least 10-12 Implants and participates in additional surgical procedures.

In the advanced grafting course each participant performs at least two open sinus augmentations and participates in other surgical augmentation procedures. A custom tailored programs can be designed according to the participant's needs.

The program includes utilization of innovative state of the art techniques, materials and surgical tools.

The course takes place in the university of Belgrade. Participants will receive their certificates from the university upon completion of the course.

To find out more about these One of a kind, leading, practical courses
visit our website at: www.handsoncourse.com

or contact us directly:

Email: drmazor@netvision.net.il | lolean1@yahoo.com, Tel. +972-50-5321885



**Think all membranes
are the same?**

Think again.

Only OSSIX™ PLUS™ (resorbable collagen membrane) has the unique GLYMATRIX™ Cross-Linking Technology.

- Retains functional integrity/barrier function for 4 to 6 months*, allowing for the regenerative process to occur
- Uses a natural nonenzymatic Glycation process to optimize healing
- Better handling characteristics and excellent functional integrity

Get all the benefits you want, without compromising!

**Order OSSIX™ PLUS™; call 1-866-273-7846
or visit www.orapharma.com**



OSSIX™ PLUS™
THE RESORBABLE COLLAGEN MEMBRANE

*Data on file, ColBar LifeScience Ltd.

oraPHARMA, inc.

© OraPharma, Inc. 2009 Rx only. Please refer to the package insert for further details. OSP-192-09 3/09
OSSIX™ PLUS™ is a trademark of OraPharma, Inc. GLYMATRIX™ is a trademark of ColBar LifeScience Ltd.